<?xml version="1.0" encoding="UTF-8"?>
<svg height="778.0" width="557.939" xmlns="http://www.w3.org/2000/svg">
 <g id="page" xmlns:svgx="http://www.xml-cml.org/schema/svgx">
  <path style="fill:none;stroke:rgb(0,0,0);stroke-width:1.0;" d="M62.360 53.720 L545.670 53.720 "/>
  <g begin="text">
   <text y="49.34" x="62.362,66.842,71.322,74.862,77.672,82.052,85.182,87.962,92.542,96.922,100.462,104.002,105.882,110.362,115.052,117.832,123.042,125.022,127.802,133.012,138.222,141.002,143.922,148.502,153.712,156.632" svgx:width="0.45,0.45,0.35,0.28,0.44,0.31,0.28,0.46,0.44,0.35,0.35,0.19,0.45,0.47,0.28,0.52,0.2,0.28,0.52,0.52,0.28,0.29,0.46,0.52,0.29,0.28" style="fill:rgb(0,0,0);font-family:GillSansStd-Italic;font-size:10.0px;stroke:none;">Poster session 2, 20 (s1) </text>
   <text y="49.34" x="530.672,535.672,540.672" svgx:width="0.5,0.5,0.5" style="fill:rgb(0,0,0);font-family:GillSansStd;font-size:10.0px;stroke:none;">385</text>
  </g>
  <g begin="text">
   <text y="768.0" x="355.802,363.932,368.622,370.502,373.312,375.192,380.092,381.972,386.352,389.132,393.712,397.562,399.442,403.822,406.952,411.432,414.972,416.852,420.392,423.172,425.572,430.052,434.742,437.872,442.562,447.252" svgx:width="0.81,0.47,0.19,0.28,0.19,0.49,0.19,0.44,0.28,0.46,0.38,0.19,0.44,0.31,0.45,0.35,0.19,0.35,0.28,0.24,0.45,0.47,0.31,0.47,0.47,0.19" style="fill:rgb(0,0,0);font-family:GillSansStd-Italic;font-size:10.0px;stroke:none;">Multiple Sclerosis Journal</text>
   <text y="768.0" x="449.132,451.912,456.912,461.912,466.912,471.912,474.102,476.882,481.882,486.882,489.072,491.852,495.082,499.662,504.662,507.892,510.672,515.672,520.672,525.672,530.672,535.672,540.672" svgx:width="0.28,0.5,0.5,0.5,0.5,0.22,0.28,0.5,0.5,0.22,0.28,0.32,0.46,0.5,0.32,0.28,0.5,0.5,0.5,0.5,0.5,0.5,0.5" style="fill:rgb(0,0,0);font-family:GillSansStd;font-size:10.0px;stroke:none;"> 2014; 20: (S1) 285–496</text>
  </g>
  <g begin="text">
   <text y="768.0" x="61.186,68.896,72.746,74.936,77.126,80.976,85.246,89.516,94.306,99.306,104.306,109.206,111.396,115.776,121.296" svgx:width="0.77,0.38,0.22,0.22,0.38,0.43,0.43,0.48,0.5,0.5,0.5,0.22,0.44,0.55,0.77" style="fill:rgb(0,0,0);font-family:GillSansStd;font-size:10.0px;stroke:none;">msj.sagepub.com</text>
  </g>
  <path style="fill:none;stroke:rgb(0,0,0);stroke-width:0.25;" d="M163.130 122.160 L208.870 122.160 "/>
  <path style="fill:none;stroke:rgb(0,0,0);stroke-width:0.44;" d="M62.360 721.160 L121.100 721.160 "/>
  <g begin="text">
   <text y="76.959" x="62.362,67.861,72.361,76.861" svgx:width="0.61,0.5,0.5,0.5" style="fill:rgb(0,0,0);font-family:TimesNewRomanPS-BoldMT;font-size:9.0px;stroke:none;">P725</text>
   <text y="87.957" x="62.362,68.86,73.36,78.364,81.361,84.862,87.859,91.855,95.851,100.351,102.853,107.857,112.357,114.859,117.109,121.609,126.613,129.61,132.112,135.109,137.611,142.615,145.612,148.114,152.614,160.111,167.608,172.108,175.105,179.605,183.601,188.101,190.351,195.355,199.351,204.355,208.855,211.105,216.109,220.105,224.605,232.102,236.602,239.599,243.595,247.096" svgx:width="0.72,0.5,0.56,0.33,0.39,0.33,0.44,0.44,0.5,0.28,0.56,0.5,0.28,0.25,0.5,0.56,0.33,0.28,0.33,0.28,0.56,0.33,0.28,0.5,0.83,0.83,0.5,0.33,0.5,0.44,0.5,0.25,0.56,0.44,0.56,0.5,0.25,0.56,0.44,0.5,0.83,0.5,0.33,0.44,0.39,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPS-BoldMT;font-size:9.0px;stroke:none;">Non-steroidal anti-inflammatory drug promotes </text>
   <text y="98.955" x="62.362,66.358,70.354,77.851,82.351,86.347,88.849,91.351,96.355,100.855,103.852,106.354,110.854" svgx:width="0.44,0.44,0.83,0.5,0.44,0.28,0.28,0.56,0.5,0.33,0.28,0.5,0.56" style="fill:rgb(0,0,0);font-family:TimesNewRomanPS-BoldMT;font-size:9.0px;stroke:none;">remyelination</text>
   <text y="109.953" x="62.362,68.86,71.11,76.114,79.111,83.107,85.609,89.11,93.61,97.606" svgx:width="0.72,0.25,0.56,0.33,0.44,0.28,0.39,0.5,0.44,0.33" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">A Preisner</text>
   <text y="107.439" x="100.603" svgx:width="0.5" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:5.85px;stroke:none;">1</text>
   <text y="109.959" x="103.528,105.778,108.028,113.032,115.282,121.78,124.282,128.782,131.779,135.775,139.771,144.271" svgx:width="0.25,0.25,0.56,0.25,0.72,0.28,0.5,0.33,0.44,0.44,0.5,0.28" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">, S Albrecht</text>
   <text y="107.439" x="146.772" svgx:width="0.5" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:5.85px;stroke:none;">1</text>
   <text y="109.959" x="149.697,151.947,154.197,160.695,162.945,168.948,173.448" svgx:width="0.25,0.25,0.72,0.25,0.67,0.5,0.28" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">, Q Cui</text>
   <text y="107.439" x="175.95" svgx:width="0.5" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:5.85px;stroke:none;">2</text>
   <text y="109.959" x="178.875,181.125,183.375,188.379,190.629,197.127,201.627,205.623,210.123" svgx:width="0.25,0.25,0.56,0.25,0.72,0.5,0.44,0.5,0.44" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">, S Hucke</text>
   <text y="107.439" x="214.118" svgx:width="0.5" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:5.85px;stroke:none;">3</text>
   <text y="109.959" x="217.044,219.294,221.544,227.547,229.797,236.295,240.291,243.288,245.79,252.792,256.788,261.288" svgx:width="0.25,0.25,0.67,0.25,0.72,0.44,0.33,0.28,0.78,0.44,0.5,0.5" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">, C Hartmann</text>
   <text y="107.439" x="265.787" svgx:width="0.5" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:5.85px;stroke:none;">4</text>
   <text y="109.959" x="268.712,270.962,273.212,281.213" svgx:width="0.25,0.25,0.89,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">, M </text>
   <text y="120.957" x="62.36,67.859,71.855,76.355,80.351,82.853" svgx:width="0.61,0.44,0.5,0.44,0.28,0.5" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">Taketo</text>
   <text y="118.439" x="87.355" svgx:width="0.5" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:5.85px;stroke:none;">5</text>
   <text y="120.959" x="90.28,92.53,94.78,98.281,100.531,107.029,111.529,114.031,118.027" svgx:width="0.25,0.25,0.39,0.25,0.72,0.5,0.28,0.44,0.28" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">, J Antel</text>
   <text y="118.439" x="120.529" svgx:width="0.5" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:5.85px;stroke:none;">2</text>
   <text y="120.959" x="123.453,125.703,127.953,133.452,135.702,142.201,144.702,149.202,151.704" svgx:width="0.25,0.25,0.61,0.25,0.72,0.28,0.5,0.28,0.44" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">, L Klotz</text>
   <text y="118.439" x="155.7" svgx:width="0.5" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:5.85px;stroke:none;">3</text>
   <text y="120.959" x="158.625,160.875,163.125,168.624,170.874,177.372,181.872,186.372,188.874,195.876,199.872,204.372" svgx:width="0.25,0.25,0.61,0.25,0.72,0.5,0.5,0.28,0.78,0.44,0.5,0.5" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">, T Kuhlmann</text>
   <text y="118.439" x="208.872" svgx:width="0.5" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:5.85px;stroke:none;">1</text>
   <text y="129.437" x="62.365" svgx:width="0.5" style="fill:rgb(0,0,0);font-family:TimesNewRomanPS-ItalicMT;font-size:5.85px;stroke:none;">1</text>
   <text y="131.959" x="65.258,71.711,76.166,78.623,82.574,86.525,89.981,93.437,95.894,98.351,102.302,104.507,110.96,115.415,118.871,123.326,125.783,128.24,132.695,135.152,137.357,144.809,149.264,153.719,157.175,159.632,163.583,167.039,169.244,171.449,174.401,178.856,182.312,184.769,187.226,189.683,194.138,196.595,200.546,202.751,207.206,209.663,211.868,217.826,221.777,226.232,229.688,234.143,238.598,243.053,245.51,249.965,254.42,256.877,261.332,265.787,269.738,271.988" svgx:width="0.72,0.5,0.28,0.44,0.44,0.39,0.39,0.28,0.28,0.44,0.25,0.72,0.5,0.39,0.5,0.28,0.28,0.5,0.28,0.25,0.83,0.5,0.5,0.39,0.28,0.44,0.39,0.25,0.25,0.33,0.5,0.39,0.28,0.28,0.28,0.5,0.28,0.44,0.25,0.5,0.28,0.25,0.67,0.44,0.5,0.39,0.5,0.5,0.5,0.28,0.5,0.5,0.28,0.5,0.5,0.44,0.25,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPS-ItalicMT;font-size:9.0px;stroke:none;">University Hospital Münster, Institute of Neuropathology, </text>
   <text y="142.957" x="62.36,69.812,74.267,78.722,82.178,84.635,88.586,92.042,94.247,96.452,102.905,106.856,110.312,116.765,121.22,125.675,129.626,131.831" svgx:width="0.83,0.5,0.5,0.39,0.28,0.44,0.39,0.25,0.25,0.72,0.44,0.39,0.72,0.5,0.5,0.44,0.25,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPS-ItalicMT;font-size:9.0px;stroke:none;">Münster, Germany, </text>
   <text y="140.439" x="134.037" svgx:width="0.5" style="fill:rgb(0,0,0);font-family:TimesNewRomanPS-ItalicMT;font-size:5.85px;stroke:none;">2</text>
   <text y="142.959" x="136.933,144.385,148.336,154.789,157.246,159.703,162.16,164.365,170.818,175.273,177.73,181.681,185.632,189.088,192.544,195.001,197.458,201.409,203.614,205.819,213.271,217.726,222.181,224.638,228.094,232.045,236.5,238.957,241.162,247.12,251.071,255.526,258.982,263.437,265.894,270.349,274.804,277.261,281.212,285.667,288.169" svgx:width="0.83,0.44,0.72,0.28,0.28,0.28,0.25,0.72,0.5,0.28,0.44,0.44,0.39,0.39,0.28,0.28,0.44,0.25,0.25,0.83,0.5,0.5,0.28,0.39,0.44,0.5,0.28,0.25,0.67,0.44,0.5,0.39,0.5,0.28,0.5,0.5,0.28,0.44,0.5,0.28,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPS-ItalicMT;font-size:9.0px;stroke:none;">McGill University, Montreal Neurological </text>
   <text y="153.957" x="62.359,65.311,69.766,73.222,75.679,78.136,80.593,85.048,87.505,91.456,93.661,95.866,103.318,107.773,112.228,114.685,118.141,122.092,126.547,129.004,131.209,133.414,139.867,145.825,148.03,150.235,156.193,160.648,165.103,169.558,174.013,178.468,180.673" svgx:width="0.33,0.5,0.39,0.28,0.28,0.28,0.5,0.28,0.44,0.25,0.25,0.83,0.5,0.5,0.28,0.39,0.44,0.5,0.28,0.25,0.25,0.72,0.67,0.25,0.25,0.67,0.5,0.5,0.5,0.5,0.5,0.25,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPS-ItalicMT;font-size:9.0px;stroke:none;">Institute, Montreal, QC, Canada, </text>
   <text y="151.439" x="182.88" svgx:width="0.5" style="fill:rgb(0,0,0);font-family:TimesNewRomanPS-ItalicMT;font-size:5.85px;stroke:none;">3</text>
   <text y="153.959" x="185.776,192.229,196.684,199.141,203.092,207.043,210.499,213.955,216.412,218.869,222.82,225.025,231.478,235.933,239.389,243.844,246.301,248.758,253.213,255.67,257.875,265.327,269.782,274.237,277.693,280.15,284.101,287.557,289.807" svgx:width="0.72,0.5,0.28,0.44,0.44,0.39,0.39,0.28,0.28,0.44,0.25,0.72,0.5,0.39,0.5,0.28,0.28,0.5,0.28,0.25,0.83,0.5,0.5,0.39,0.28,0.44,0.39,0.25,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPS-ItalicMT;font-size:9.0px;stroke:none;">University Hospital Münster, </text>
   <text y="164.957" x="62.359,68.317,70.774,73.231,77.686,80.143,84.094,86.299,88.756,93.211,96.667,98.872,104.83,108.781,113.236,116.692,121.147,123.604,128.059,132.514,136.465,138.67,140.875,148.327,152.782,157.237,160.693,163.15,167.101,170.557,172.762,174.967,181.42,185.371,188.827,195.28,199.735,204.19,208.141,210.346" svgx:width="0.67,0.28,0.28,0.5,0.28,0.44,0.25,0.28,0.5,0.39,0.25,0.67,0.44,0.5,0.39,0.5,0.28,0.5,0.5,0.44,0.25,0.25,0.83,0.5,0.5,0.39,0.28,0.44,0.39,0.25,0.25,0.72,0.44,0.39,0.72,0.5,0.5,0.44,0.25,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPS-ItalicMT;font-size:9.0px;stroke:none;">Clinic for Neurology, Münster, Germany, </text>
   <text y="162.439" x="212.553" svgx:width="0.5" style="fill:rgb(0,0,0);font-family:TimesNewRomanPS-ItalicMT;font-size:5.85px;stroke:none;">4</text>
   <text y="164.959" x="215.448,221.901,226.356,228.813,232.764,236.715,240.171,243.627,246.084,248.541,252.492,254.697,261.15,265.605,269.061,273.516,275.973,278.43,282.885,285.387" svgx:width="0.72,0.5,0.28,0.44,0.44,0.39,0.39,0.28,0.28,0.44,0.25,0.72,0.5,0.39,0.5,0.28,0.28,0.5,0.28,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPS-ItalicMT;font-size:9.0px;stroke:none;">University Hospital </text>
   <text y="175.957" x="62.358,69.81,74.265,78.72,82.176,84.633,88.584,92.04,94.245,96.45,99.402,103.857,107.313,109.77,112.227,114.684,119.139,121.596,125.547,127.752,132.207,134.664,136.869,144.321,148.776,152.232,156.183,160.638,163.095,167.55,171.006,174.957,178.908,181.365,185.316,187.773,192.228,194.685,196.89,204.342,208.293,212.748,215.205,219.156,221.613,226.068,230.019,232.224,234.429,241.881,246.336,250.791,254.247,256.704,260.655,264.111,266.361" svgx:width="0.83,0.5,0.5,0.39,0.28,0.44,0.39,0.25,0.25,0.33,0.5,0.39,0.28,0.28,0.28,0.5,0.28,0.44,0.25,0.5,0.28,0.25,0.83,0.5,0.39,0.44,0.5,0.28,0.5,0.39,0.44,0.44,0.28,0.44,0.28,0.5,0.28,0.25,0.83,0.44,0.5,0.28,0.44,0.28,0.5,0.44,0.25,0.25,0.83,0.5,0.5,0.39,0.28,0.44,0.39,0.25,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPS-ItalicMT;font-size:9.0px;stroke:none;">Münster, Institute of Musculosceletal Medicine, Münster, </text>
   <text y="186.955" x="62.358,68.811,72.762,76.218,82.671,87.126,91.581,95.532,97.737" svgx:width="0.72,0.44,0.39,0.72,0.5,0.5,0.44,0.25,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPS-ItalicMT;font-size:9.0px;stroke:none;">Germany, </text>
   <text y="184.439" x="99.946" svgx:width="0.5" style="fill:rgb(0,0,0);font-family:TimesNewRomanPS-ItalicMT;font-size:5.85px;stroke:none;">5</text>
   <text y="186.959" x="102.841,108.799,112.75,117.205,119.662,124.117,126.322,132.775,137.23,139.687,143.638,147.589,151.045,154.501,156.958,159.415,163.366,165.571,172.024,175.48,179.935,184.39,188.845,193.3,195.757,199.708,201.913,206.368,210.319,214.774,219.229,223.684,226.141,228.346,232.801,235.258,237.463,244.915,248.866,253.321,255.778,259.729,262.186,266.641,270.637" svgx:width="0.67,0.44,0.5,0.28,0.5,0.25,0.72,0.5,0.28,0.44,0.44,0.39,0.39,0.28,0.28,0.44,0.25,0.72,0.39,0.5,0.5,0.5,0.5,0.28,0.44,0.25,0.5,0.44,0.5,0.5,0.5,0.28,0.25,0.5,0.28,0.25,0.83,0.44,0.5,0.28,0.44,0.28,0.5,0.44,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPS-ItalicMT;font-size:9.0px;stroke:none;">Kyoto University Graduate School of Medicine </text>
   <text y="197.957" x="62.359,67.318,71.773,75.229,79.684,82.141,86.596,91.051,94.003,96.208,102.166,106.621,111.076,115.531,119.482,122.434,126.385,130.84,135.295,137.5,139.705,146.158,150.109,154.564,159.019,162.475,164.932,171.385,175.336,179.791,182.248,184.453,188.908,191.365,193.57,199.024,203.479,207.934,211.39,217.843,222.298,226.249,230.704,233.161,237.616,242.071,246.022,248.227,250.432,256.39,260.341,264.796,267.253,271.708,273.913,276.118,280.069,284.524,288.979,293.434" svgx:width="0.56,0.5,0.39,0.5,0.28,0.5,0.5,0.33,0.25,0.67,0.5,0.5,0.5,0.44,0.33,0.44,0.5,0.5,0.25,0.25,0.72,0.44,0.5,0.5,0.39,0.28,0.72,0.44,0.5,0.28,0.25,0.5,0.28,0.25,0.61,0.5,0.5,0.39,0.72,0.5,0.44,0.5,0.28,0.5,0.5,0.44,0.25,0.25,0.67,0.44,0.5,0.28,0.5,0.25,0.25,0.44,0.5,0.5,0.5,0.5" style="fill:rgb(0,0,0);font-family:TimesNewRomanPS-ItalicMT;font-size:9.0px;stroke:none;">Yoshida- Konoé-cho, Department of Pharmacology, Kyoto, Japan</text>
   <text y="224.957" x="62.359,68.272,72.682,76.588,81.502,85.912,89.656,94.066,98.98,103.894,108.808,111.715" svgx:width="0.67,0.5,0.44,0.56,0.5,0.44,0.5,0.56,0.56,0.56,0.33,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPS-BoldMT;font-size:9.0px;stroke:none;">Background: </text>
   <text y="224.957" x="113.776,116.683,121.093,124.0,126.412,130.318,137.23,144.142,148.048,150.46,152.872,157.282,161.692,163.753,167.659,172.069,176.479,178.54,182.95,186.856,189.763,196.675,200.581,204.991,208.897,213.307,215.719,217.78,222.19,226.096,233.008,237.419,241.325,243.737,246.149,250.559,254.465,256.877,259.289,263.699,268.109,270.17,274.076,278.486,282.896,285.308,288.215,290.627,295.037" svgx:width="0.33,0.5,0.33,0.28,0.44,0.78,0.78,0.44,0.28,0.28,0.5,0.5,0.25,0.44,0.5,0.5,0.25,0.5,0.44,0.33,0.78,0.44,0.5,0.44,0.5,0.28,0.25,0.5,0.44,0.78,0.5,0.44,0.28,0.28,0.5,0.44,0.28,0.28,0.5,0.5,0.25,0.44,0.5,0.5,0.28,0.33,0.28,0.5,0.33" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">Inflammation and permanent demyelination contrib-</text>
   <text y="235.955" x="62.359,66.769,69.181,73.087,75.184,77.596,82.006,84.103,88.009,92.419,96.829,101.239,105.145,107.557,109.654,114.064,117.97,124.882,128.788,133.198,137.104,139.201,143.107,147.517,151.927,154.024,156.436,160.846,164.257,167.668,169.828,171.925,174.337,178.747,182.653,184.75,188.656,192.562,196.972,200.383,204.289,206.386,209.293,213.703,216.61,218.707,223.117,226.024,230.434,234.844,237.751,241.657,245.068,248.479,250.891,255.301,259.207,261.304,265.714,269.62,274.03,276.937,281.347,283.759,288.169,292.579,294.991" svgx:width="0.5,0.28,0.44,0.25,0.28,0.5,0.25,0.44,0.5,0.5,0.5,0.44,0.28,0.25,0.5,0.44,0.78,0.44,0.5,0.44,0.25,0.44,0.5,0.5,0.25,0.28,0.5,0.39,0.39,0.25,0.25,0.28,0.5,0.44,0.25,0.44,0.44,0.5,0.39,0.44,0.25,0.33,0.5,0.33,0.25,0.5,0.33,0.5,0.5,0.33,0.44,0.39,0.39,0.28,0.5,0.44,0.25,0.5,0.44,0.5,0.33,0.5,0.28,0.5,0.5,0.28,0.33" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">ute to axonal damage and loss, the cause for progressive neurologi-</text>
   <text y="246.953" x="62.359,66.265,70.171,72.583,74.833,81.556,85.966,89.872,92.779,95.191,99.097,101.509,103.921,106.171,112.894,117.304,121.714,125.125,129.031,131.938,136.348,140.254,144.664,146.914,153.637,156.049,160.459,162.709,169.432,177.343,182.257,184.507,191.23,195.64,199.546,201.958,204.37,208.276,212.686,215.098,218.509,220.669,222.919,229.642,236.05,238.462,241.207,244.114,248.02,250.927,254.833,259.243,261.655,264.067,267.973,270.385,272.797,277.207,281.617,283.867,290.59,295.0,297.997" svgx:width="0.44,0.44,0.28,0.25,0.55,0.5,0.44,0.33,0.28,0.44,0.28,0.28,0.25,0.55,0.5,0.5,0.39,0.44,0.33,0.5,0.44,0.5,0.25,0.55,0.28,0.5,0.25,0.55,0.89,0.56,0.25,0.55,0.5,0.44,0.28,0.28,0.44,0.5,0.28,0.39,0.25,0.25,0.55,0.72,0.28,0.33,0.33,0.44,0.33,0.44,0.5,0.28,0.28,0.44,0.28,0.28,0.5,0.5,0.25,0.55,0.5,0.33,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">cal deficit observed in MS patients. Differentiation of </text>
   <text y="257.951" x="62.359,66.769,69.181,71.593,76.003,80.413,84.823,88.729,93.139,97.549,100.456,104.866,109.276,111.688,114.1,118.006,120.418,122.668,123.631,128.041,130.948,134.854,138.76,143.17,146.077,149.488,153.898,156.805,159.055,160.018,163.924,167.83,170.242,172.654,176.065,178.315,179.278,182.185,188.593,193.507,199.42,202.831,205.738,207.988,208.951,211.363,215.773,218.023,218.986,225.898,230.308,234.214,236.626,239.038,243.448,247.354,249.766,252.178,256.588,260.998,263.248,264.211,268.621,271.033,273.445,277.855,282.265,286.675,290.581,294.991" svgx:width="0.5,0.28,0.28,0.5,0.5,0.5,0.44,0.5,0.5,0.33,0.5,0.5,0.28,0.28,0.44,0.28,0.25,0.55,0.5,0.33,0.44,0.44,0.5,0.33,0.39,0.5,0.33,0.25,0.55,0.44,0.44,0.28,0.28,0.39,0.25,0.55,0.33,0.72,0.56,0.67,0.39,0.33,0.25,0.55,0.28,0.5,0.25,0.55,0.78,0.5,0.44,0.28,0.28,0.5,0.44,0.28,0.28,0.5,0.5,0.25,0.55,0.5,0.28,0.28,0.5,0.5,0.5,0.44,0.5,0.33" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">oligodendroglial precursor cells (OPCs) to myelinating oligoden-</text>
   <text y="268.949" x="62.359,66.769,69.676,74.086,77.992,82.402,84.814,88.72,92.131,94.201,96.613,100.024,102.094,106.504,109.411,111.823,115.729,120.139,122.209,124.621,131.533,135.943,139.849,142.261,145.168,149.074,153.484,155.644,157.714,160.621,164.527,167.938,172.348,174.76,177.172,179.584,183.994,188.404,190.474,192.886,197.296,199.366,201.778,204.19,211.102,213.514,215.926,219.832,224.242,226.312,229.219,233.125,240.037,244.447,248.354,250.766,253.178,257.587,261.493,263.905,266.317,270.727,275.137,277.297,279.367,283.273,286.685,291.095,295.001" svgx:width="0.5,0.33,0.5,0.44,0.5,0.28,0.44,0.39,0.25,0.28,0.39,0.25,0.5,0.33,0.28,0.44,0.5,0.25,0.28,0.78,0.5,0.44,0.28,0.33,0.44,0.5,0.25,0.25,0.33,0.44,0.39,0.5,0.28,0.28,0.28,0.5,0.5,0.25,0.28,0.5,0.25,0.28,0.28,0.78,0.28,0.28,0.44,0.5,0.25,0.33,0.44,0.78,0.5,0.44,0.28,0.28,0.5,0.44,0.28,0.28,0.5,0.5,0.25,0.25,0.44,0.39,0.5,0.44,0.33" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">drocytes is often impaired, resulting in limited remyelination, espe-</text>
   <text y="279.947" x="62.359,66.265,68.677,72.583,74.995,77.407,81.817,84.643,87.055,91.465,94.291,98.197,102.607,105.514,109.924,114.334,116.746,120.652,123.478,131.389,136.303,139.129,141.541,145.447,148.858,151.27,155.68,160.09,163.501,165.661,168.487,176.398,180.808,183.22,185.632,188.044,192.454,194.866,198.772,201.598,206.008,209.914,212.326,216.736,223.144,227.05,231.46,234.871,237.031,239.857,243.763,250.675,255.085,259.495,263.905,266.731,269.143,273.553,277.459,284.371,287.197,289.609,294.019,298.015" svgx:width="0.44,0.28,0.44,0.28,0.28,0.5,0.25,0.28,0.5,0.25,0.44,0.5,0.33,0.5,0.5,0.28,0.44,0.25,0.89,0.56,0.25,0.28,0.44,0.39,0.28,0.5,0.5,0.39,0.25,0.25,0.89,0.5,0.28,0.28,0.28,0.5,0.28,0.44,0.25,0.5,0.44,0.28,0.5,0.72,0.44,0.5,0.39,0.25,0.25,0.44,0.78,0.5,0.5,0.5,0.25,0.28,0.5,0.44,0.78,0.25,0.28,0.5,0.44,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">cially in chronic MS lesions. Multiple pathways, among them the </text>
   <text y="290.945" x="62.359,70.765,75.175,77.587,79.999,84.409,88.315,90.727,94.633,97.54,101.446,105.352,107.764,111.67,116.08,118.492,122.902,125.107,128.518,130.93,135.34,139.75,143.656,146.068,148.48,152.89,157.3,159.505,163.411,167.317,170.728,174.634,178.54,182.95,186.856,189.061,193.471,197.377,200.788,202.993,207.403,211.309,215.215,219.625,221.83,224.242,231.154,235.564,237.977,240.389,244.295,248.201,250.613,254.519,258.929,261.134,263.546,267.956,270.16,274.066,278.477,282.887,285.298,288.206,290.617,295.027" svgx:width="0.94,0.5,0.28,0.28,0.5,0.44,0.28,0.44,0.33,0.44,0.44,0.28,0.44,0.5,0.28,0.5,0.25,0.39,0.28,0.5,0.5,0.44,0.28,0.28,0.5,0.5,0.25,0.44,0.44,0.39,0.44,0.44,0.5,0.44,0.25,0.5,0.44,0.39,0.25,0.5,0.44,0.44,0.5,0.25,0.28,0.78,0.5,0.28,0.28,0.44,0.44,0.28,0.44,0.5,0.25,0.28,0.5,0.25,0.44,0.5,0.5,0.28,0.33,0.28,0.5,0.33" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">Wnt/beta-catenin signaling cascade has been implicated to contrib-</text>
   <text y="301.943" x="62.359,66.769,69.181,73.087,75.085,77.497,81.907,83.905,86.812,90.718,97.63,102.04,105.946,108.358,110.77,115.18,119.086,121.498,123.91,128.32,132.73,134.728,137.635,141.541,143.953,146.365,150.775,153.682,157.588,159.586,161.998,166.408,168.406,176.317,181.231,183.391,185.389,188.296,192.706,194.704,198.61,202.516,205.423,207.835,210.247,214.153,217.06,219.058,222.469,224.881,229.291,233.701,236.113,240.019,243.43,245.428,251.836,255.742,257.74,261.646,266.056,270.466,272.878,277.288,279.286,282.697,287.107,291.517,298.015" svgx:width="0.5,0.28,0.44,0.25,0.28,0.5,0.25,0.33,0.44,0.78,0.5,0.44,0.28,0.28,0.5,0.44,0.28,0.28,0.5,0.5,0.25,0.33,0.44,0.28,0.28,0.5,0.33,0.44,0.25,0.28,0.5,0.25,0.89,0.56,0.25,0.25,0.33,0.5,0.25,0.44,0.44,0.33,0.28,0.28,0.44,0.33,0.25,0.39,0.28,0.5,0.5,0.28,0.44,0.39,0.25,0.72,0.44,0.25,0.44,0.5,0.5,0.28,0.5,0.25,0.39,0.5,0.5,0.72,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">ute to remyelination failure in MS. In earlier studies we could show </text>
   <text y="312.941" x="62.359,64.771,69.181,73.087,75.499,77.425,81.331,83.257,87.667,92.077,96.487,99.394,102.805,105.217,109.123,112.03,116.44,118.852,123.262,127.168,129.58,131.506,135.412,139.822,142.234,144.646,147.553,149.965,154.375,157.282,159.694,163.6,170.512,177.424,181.33,183.742,188.152,191.059,195.469,197.395,201.805,204.712,209.122,213.532,215.458,218.365,224.773,229.687,236.095,239.002,245.41,248.317,250.243,252.655,256.066,257.992,261.898,266.308,268.72,272.626,274.552,276.964,281.374,283.3,287.71,290.617,295.027" svgx:width="0.28,0.5,0.44,0.28,0.25,0.44,0.25,0.5,0.5,0.5,0.33,0.39,0.28,0.44,0.33,0.5,0.28,0.5,0.44,0.28,0.25,0.44,0.5,0.28,0.28,0.33,0.28,0.5,0.33,0.28,0.44,0.78,0.78,0.44,0.28,0.5,0.33,0.5,0.25,0.5,0.33,0.5,0.5,0.25,0.33,0.72,0.56,0.72,0.33,0.72,0.33,0.25,0.28,0.39,0.25,0.44,0.5,0.28,0.44,0.25,0.28,0.5,0.25,0.5,0.33,0.5,0.33" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">that a non-steroidal anti-inflammatory drug (NSAID) is able to pro-</text>
   <text y="323.939" x="62.359,69.271,73.681,76.093,79.999,82.159,85.57,87.982,92.392,96.802,99.214,102.121,104.533,108.439,112.345,116.755,119.167,121.579,125.989,128.149,130.561,134.971,138.877,141.037,145.447,147.859,150.604,153.511,157.417,160.324,164.23,168.64,171.052,173.464,177.37,179.782,182.194,186.604,191.014,193.174,197.584,200.491,202.651,209.563,213.973,216.88,219.292,223.702,227.608,229.768,234.178,236.59,239.003,243.413,247.823,252.233,256.139,260.549,264.959,267.866,272.276,276.182,280.592,283.004,286.91,290.321" svgx:width="0.78,0.5,0.28,0.44,0.25,0.39,0.28,0.5,0.5,0.28,0.33,0.28,0.44,0.44,0.5,0.28,0.28,0.5,0.25,0.28,0.5,0.44,0.25,0.5,0.28,0.33,0.33,0.44,0.33,0.44,0.5,0.28,0.28,0.44,0.28,0.28,0.5,0.5,0.25,0.5,0.33,0.25,0.78,0.5,0.33,0.28,0.5,0.44,0.25,0.5,0.28,0.28,0.5,0.5,0.5,0.44,0.5,0.5,0.33,0.5,0.44,0.5,0.28,0.44,0.39,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">mote significantly the differentiation of murine oligodendrocytes.</text>
   <text y="334.937" x="62.359,69.361,74.365,77.362,81.358,85.354,88.351,90.853,95.353,99.349,102.85,105.847" svgx:width="0.78,0.56,0.33,0.44,0.44,0.33,0.28,0.5,0.44,0.39,0.33,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPS-BoldMT;font-size:9.0px;stroke:none;">Objectives: </text>
   <text y="334.937" x="109.195,115.693,118.195,125.197,127.447,128.545,133.045,136.042,138.292,139.39,143.89,148.39,151.387,153.637,154.735,158.236,160.738,165.238,169.738,174.238,176.488,177.586,184.084,188.08,191.581,193.831,194.929,199.429,201.679,203.929,205.027,207.529,212.029,214.279,215.377,219.877,223.873,226.375,230.371,233.368,240.37,242.872,247.372,251.368,253.618,254.716,261.214,265.714,269.71,272.212,276.712,280.708,283.705,285.955,287.053,289.555,294.055,298.051" svgx:width="0.72,0.28,0.78,0.25,0.55,0.5,0.33,0.25,0.55,0.5,0.5,0.33,0.25,0.55,0.39,0.28,0.5,0.5,0.5,0.25,0.55,0.72,0.44,0.39,0.25,0.55,0.5,0.25,0.25,0.55,0.28,0.5,0.25,0.55,0.5,0.44,0.28,0.44,0.33,0.78,0.28,0.5,0.44,0.25,0.55,0.72,0.5,0.44,0.28,0.5,0.44,0.33,0.25,0.55,0.28,0.5,0.44,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">Aim of our study was 1. to determine whether the </text>
   <text y="345.935" x="62.359,68.857,73.861,80.359,83.356,89.854,92.617,97.117,100.114,104.614,111.616,116.116,118.618,122.614,126.115,128.878,132.874,135.376,138.877,143.377,146.14,148.642,153.142,157.138,159.901,164.401,166.903,169.738,172.735,176.731,179.728,183.724,188.224,190.726,193.228,197.224,199.726,202.228,206.728,211.228,213.991,218.491,221.488,224.251,228.751,233.251,240.253,244.249,248.749,251.512,256.012,258.514,261.016,265.516,270.016,274.516,278.512,283.012,287.512,290.509,295.009" svgx:width="0.72,0.56,0.72,0.33,0.72,0.25,0.5,0.33,0.5,0.78,0.5,0.28,0.44,0.39,0.25,0.44,0.28,0.39,0.5,0.25,0.28,0.5,0.44,0.25,0.5,0.28,0.33,0.33,0.44,0.33,0.44,0.5,0.28,0.28,0.44,0.28,0.28,0.5,0.5,0.25,0.5,0.33,0.25,0.5,0.5,0.78,0.44,0.5,0.25,0.5,0.28,0.28,0.5,0.5,0.5,0.44,0.5,0.5,0.33,0.5,0.33" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">NSAID promotes also the differentiation of human oligodendro-</text>
   <text y="356.933" x="62.359,66.355,70.855,73.357,77.353,80.854,83.104,84.958,89.458,91.708,93.958,95.812,98.314,102.814,105.064,106.918,110.419,112.921,117.421,121.921,126.421,128.671,130.525,133.027,137.527,141.523,143.773,145.627,148.624,152.62,159.622,164.122,168.118,170.62,173.122,177.622,181.618,184.12,186.622,191.122,195.622,197.872,199.726,204.226,207.223,211.723,218.725,223.225,225.727,228.229,232.729,237.229,239.479,241.333,245.329,249.325,253.825,257.821,261.817,264.319,266.821,271.321,273.571,275.425,279.925,282.922,285.172,287.026,289.528,294.028,298.024" svgx:width="0.44,0.5,0.28,0.44,0.39,0.25,0.55,0.5,0.25,0.25,0.55,0.28,0.5,0.25,0.55,0.39,0.28,0.5,0.5,0.5,0.25,0.55,0.28,0.5,0.44,0.25,0.55,0.33,0.44,0.78,0.5,0.44,0.28,0.28,0.5,0.44,0.28,0.28,0.5,0.5,0.25,0.55,0.5,0.33,0.5,0.78,0.5,0.28,0.28,0.5,0.5,0.25,0.55,0.44,0.44,0.5,0.44,0.44,0.28,0.28,0.5,0.25,0.55,0.5,0.33,0.25,0.55,0.28,0.5,0.44,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">cytes 2. to study the remyelination promoting capacity of the </text>
   <text y="367.931" x="62.359,68.857,73.861,80.359,83.356,89.854,92.104,93.049,97.045,101.545,106.045,108.295,109.24,113.74,115.99,118.24,119.185,121.687,126.187,128.437,129.382,133.882,136.384,139.885,143.386,147.382,151.378,153.88,156.13,157.075,159.577,164.077,168.073,170.323,171.268,178.27,182.266,186.262,190.762,194.758,199.258,201.76,205.261,212.263,215.764,218.014,218.959,223.459,227.959,230.209,231.154,237.652,242.152,244.654,248.65,253.15,255.4,256.345,258.847,263.347,267.343,269.593,270.538,277.036,282.04,288.538,291.535,298.033" svgx:width="0.72,0.56,0.72,0.33,0.72,0.25,0.55,0.44,0.5,0.5,0.25,0.55,0.5,0.25,0.25,0.55,0.28,0.5,0.25,0.55,0.5,0.28,0.39,0.39,0.44,0.44,0.28,0.25,0.55,0.28,0.5,0.44,0.25,0.55,0.78,0.44,0.44,0.5,0.44,0.5,0.28,0.39,0.78,0.39,0.25,0.55,0.5,0.5,0.25,0.55,0.72,0.5,0.28,0.44,0.5,0.25,0.55,0.28,0.5,0.44,0.25,0.55,0.72,0.56,0.72,0.33,0.72,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">NSAID and 3. to dissect the mechanisms by which the NSAID </text>
   <text y="378.929" x="62.359,66.859,69.856,74.356,81.358,85.858,88.36,92.356,95.857,98.107,102.607,105.109,107.611,112.111,116.611,121.111,125.107,129.607,134.107,137.104,141.604,146.104,148.606,151.108,155.104,157.606,159.856,164.356,166.858,169.693,172.69,176.686,179.683,183.679,188.179,190.681,193.183,197.179,199.681,202.183,206.683,211.183" svgx:width="0.5,0.33,0.5,0.78,0.5,0.28,0.44,0.39,0.25,0.5,0.28,0.28,0.5,0.5,0.5,0.44,0.5,0.5,0.33,0.5,0.5,0.28,0.28,0.44,0.28,0.25,0.5,0.28,0.33,0.33,0.44,0.33,0.44,0.5,0.28,0.28,0.44,0.28,0.28,0.5,0.5,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">promotes oligodendroglial differentiation.</text>
   <text y="389.927" x="62.359,70.855,74.851,77.848,82.852,87.352,92.356,95.857,98.854" svgx:width="0.94,0.44,0.33,0.56,0.5,0.56,0.39,0.33,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPS-BoldMT;font-size:9.0px;stroke:none;">Methods: </text>
   <text y="389.927" x="101.257,107.755,112.255,119.257,123.253,127.753,130.156,134.152,138.652,143.152,145.555,152.557,157.057,160.054,162.556,167.056,171.052,173.455,177.955,180.457,182.959,187.459,191.959,196.459,200.455,204.955,209.455,212.452,216.952,221.452,223.954,226.456,230.452,232.954,235.357,239.353,243.349,245.851,248.353,250.756,254.752,259.252,261.754,264.256,268.756,271.753,275.749,277.999,280.402,284.902,290.365,295.036" svgx:width="0.72,0.5,0.78,0.44,0.5,0.25,0.44,0.5,0.5,0.25,0.78,0.5,0.33,0.28,0.5,0.44,0.25,0.5,0.28,0.28,0.5,0.5,0.5,0.44,0.5,0.5,0.33,0.5,0.5,0.28,0.28,0.44,0.28,0.25,0.44,0.44,0.28,0.28,0.25,0.44,0.5,0.28,0.28,0.5,0.33,0.44,0.25,0.25,0.5,0.67,0.61,0.33" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">Human and murine oligodendroglial cell culture, qRT-</text>
   <text y="400.925" x="62.359,67.363,73.366,79.369,81.619,83.869,84.553,87.55,91.546,96.046,100.546,103.543,106.045,110.041,113.038,115.288,115.972,119.968,123.469,126.97,130.966,135.466,138.967,141.217,143.989,151.765,155.761,159.262,161.764,165.76,168.757,173.257,175.507,176.191,180.691,183.193,187.693,190.195,193.696,195.946,198.196,198.88,202.876,207.376,211.876,214.873,217.375,221.371,225.871,230.371,234.367,236.617,237.301,244.303,248.803,253.303,257.299,259.801,262.051,264.301,264.985,267.487,274.489,281.491,285.991,290.491,294.991" svgx:width="0.56,0.67,0.67,0.25,0.25,0.55,0.33,0.44,0.5,0.5,0.33,0.28,0.44,0.33,0.25,0.55,0.44,0.39,0.39,0.44,0.5,0.39,0.25,0.25,0.94,0.44,0.39,0.28,0.44,0.33,0.5,0.25,0.55,0.5,0.28,0.5,0.28,0.39,0.25,0.25,0.55,0.44,0.5,0.5,0.33,0.28,0.44,0.5,0.5,0.44,0.25,0.55,0.78,0.5,0.5,0.44,0.28,0.25,0.25,0.55,0.28,0.78,0.78,0.5,0.5,0.5,0.33" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">PCR, reporter assays, Western blots, cuprizone model, immuno-</text>
   <text y="411.923" x="62.359,66.859,69.361,72.862,75.364,79.864,83.86,88.36,92.356,99.358,101.86,105.361,107.863,110.86,114.775,117.025,119.275,124.774" svgx:width="0.5,0.28,0.39,0.28,0.5,0.44,0.5,0.44,0.78,0.28,0.39,0.28,0.33,0.5,0.25,0.25,0.61,0.89" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">histochemistry, EM</text>
   <text y="422.921" x="62.359,68.677,72.493,75.814,80.638,82.96,85.777,89.098,91.915" svgx:width="0.72,0.44,0.39,0.56,0.28,0.33,0.39,0.33,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPS-BoldMT;font-size:9.0px;stroke:none;">Results: </text>
   <text y="422.921" x="93.625,101.221,105.037,106.747,111.067,115.387,118.708,122.524,125.341,129.661,133.477,137.797,139.507,143.323,145.033,148.354,150.676,154.996,159.316,161.638,164.455,166.777,170.593,174.409,178.729,181.051,183.373,187.693,189.403,191.725,196.045,199.861,202.678,206.494,210.31,213.631,217.447,221.767,223.477,227.797,232.117,238.939,243.259,247.075,249.892,251.602,255.922,258.739,260.449,267.271,271.087,273.409,277.729,280.546,284.362,286.072,290.392,292.714,295.036" svgx:width="0.94,0.44,0.25,0.5,0.5,0.39,0.44,0.33,0.5,0.44,0.5,0.25,0.44,0.25,0.39,0.28,0.5,0.5,0.28,0.33,0.28,0.44,0.44,0.5,0.28,0.28,0.5,0.25,0.28,0.5,0.44,0.33,0.44,0.44,0.39,0.44,0.5,0.25,0.5,0.5,0.78,0.5,0.44,0.33,0.25,0.5,0.33,0.25,0.78,0.44,0.28,0.5,0.33,0.44,0.25,0.5,0.28,0.28,0.33" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">We observed a significantly increased number of mature oli-</text>
   <text y="433.919" x="62.359,66.679,70.999,75.319,79.135,83.455,87.775,90.592,94.912,98.728,103.048,105.37,109.186,112.507,114.757,115.558,119.374,122.191,124.513,128.329,131.146,133.396,134.197,138.013,142.333,146.653,148.975,151.297,153.619,157.939,162.259,164.509,165.31,169.63,172.447,174.697,175.498,177.82,182.14,185.956,188.206,189.007,192.823,197.143,203.965,208.285,212.605,216.925,221.245,225.565,227.815,228.616,230.938,235.258,237.508,238.309,242.629,246.949,253.771,257.587,261.907,264.157,264.958,269.278,271.6,273.922,278.242,282.562,286.882,290.698,295.018" svgx:width="0.5,0.5,0.5,0.44,0.5,0.5,0.33,0.5,0.44,0.5,0.28,0.44,0.39,0.25,0.55,0.44,0.33,0.28,0.44,0.33,0.25,0.55,0.44,0.5,0.5,0.28,0.28,0.28,0.5,0.5,0.25,0.55,0.5,0.33,0.25,0.55,0.28,0.5,0.44,0.25,0.55,0.44,0.5,0.78,0.5,0.5,0.5,0.5,0.5,0.25,0.55,0.28,0.5,0.25,0.55,0.5,0.5,0.78,0.44,0.5,0.25,0.55,0.5,0.28,0.28,0.5,0.5,0.5,0.44,0.5,0.33" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">godendrocytes after addition of the compound to human oligoden-</text>
   <text y="444.917" x="62.359,66.679,69.496,73.816,78.136,80.458,82.78,86.596,88.918,91.573,95.389,99.205,101.527,103.849,106.504,110.32,114.64,116.962,119.284,123.604,126.421,130.237,133.558,135.628,138.283,141.1,145.42,148.075,150.397,154.717,158.533,161.188,165.004,169.324,173.644,176.461,178.783,182.599,186.919,191.239,195.055,197.71,204.532,208.852,213.172,216.988,219.31,221.965,226.285,230.101,232.423,234.745,239.065,241.72,244.042,248.362,250.684,254.5,258.316,260.638,262.96,267.28,271.6,274.921,277.576,281.896,284.713,287.368,289.69,294.01,298.006" svgx:width="0.5,0.33,0.5,0.5,0.28,0.28,0.44,0.28,0.25,0.44,0.44,0.28,0.28,0.25,0.44,0.5,0.28,0.28,0.5,0.33,0.44,0.39,0.25,0.25,0.33,0.5,0.25,0.28,0.5,0.44,0.25,0.44,0.5,0.5,0.33,0.28,0.44,0.5,0.5,0.44,0.25,0.78,0.5,0.5,0.44,0.28,0.25,0.5,0.44,0.28,0.28,0.5,0.25,0.28,0.5,0.28,0.44,0.44,0.28,0.28,0.5,0.5,0.39,0.25,0.5,0.33,0.25,0.28,0.5,0.44,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">droglial cell cultures. In the cuprizone model daily injections of the </text>
   <text y="455.915" x="62.359,68.677,73.501,79.819,82.636,88.954,90.763,95.083,99.403,102.22,104.542,108.862,113.182,114.991,117.313,121.633,125.449,127.258,130.075,133.891,140.713,145.033,148.849,151.171,153.493,157.813,161.629,163.951,166.273,170.593,174.913,176.722,181.042,185.362,189.178,192.499,196.315,198.124,200.941,204.757,208.078,212.398,214.72,217.042,220.858,225.178,226.987,229.309,233.629,235.438,239.758,242.08,246.4,250.72,254.536,257.353,259.162,263.482,267.802,274.624,278.944,282.76,285.577,288.898,290.707,295.027,298.024" svgx:width="0.72,0.56,0.72,0.33,0.72,0.25,0.5,0.5,0.33,0.28,0.5,0.5,0.25,0.28,0.5,0.44,0.25,0.33,0.44,0.78,0.5,0.44,0.28,0.28,0.5,0.44,0.28,0.28,0.5,0.5,0.25,0.5,0.5,0.44,0.39,0.44,0.25,0.33,0.44,0.39,0.5,0.28,0.28,0.44,0.5,0.25,0.28,0.5,0.25,0.5,0.28,0.5,0.5,0.44,0.33,0.25,0.5,0.5,0.78,0.5,0.44,0.33,0.39,0.25,0.5,0.33,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">NSAID during the remyelinating phase resulted in higher numbers of </text>
   <text y="466.913" x="62.359,69.181,72.997,75.319,79.639,82.456,86.272,88.09,92.41,94.732,97.054,101.374,105.694,110.014,113.83,118.15,122.47,125.287,129.607,133.423,137.743,140.065,143.881,147.202,149.272,151.09,153.412,157.732,161.548,164.365,168.181,171.997,175.318,179.134,183.454,185.272,189.088,193.408,197.728,200.545,204.361,207.682,211.003,213.325,217.645,221.965,223.783,226.105,229.921,234.241,238.057,240.379,243.7,245.518,249.838,252.655,254.473,261.295,265.615,269.431,271.753,274.075,278.395,280.213,284.029,287.35,290.671,294.991" svgx:width="0.78,0.44,0.28,0.5,0.33,0.44,0.25,0.5,0.28,0.28,0.5,0.5,0.5,0.44,0.5,0.5,0.33,0.5,0.44,0.5,0.28,0.44,0.39,0.25,0.25,0.28,0.5,0.44,0.33,0.44,0.44,0.39,0.44,0.5,0.25,0.44,0.5,0.5,0.33,0.44,0.39,0.39,0.28,0.5,0.5,0.25,0.28,0.44,0.5,0.44,0.28,0.39,0.25,0.5,0.33,0.25,0.78,0.5,0.44,0.28,0.28,0.5,0.25,0.44,0.39,0.39,0.5,0.33" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">mature oligodendrocytes, increased expression levels of myelin asso-</text>
   <text y="477.911" x="62.359,66.175,68.497,72.313,74.635,78.451,82.771,84.625,88.945,92.761,97.081,100.897,104.218,106.072,109.888,114.208,118.528,120.382,124.198,128.014,131.83,135.646,137.968,141.784,144.601,148.417,150.739,154.555,158.875,160.729,163.546,167.362,174.184,178.504,182.32,184.642,186.964,191.284,195.1,197.422,199.744,204.064,208.384,210.238,214.558,217.879,220.201,224.521,228.841,230.695,233.017,239.839,246.661,250.981,255.301,259.621,263.941,266.263,269.584,271.906,276.226,280.042,284.362,288.178,295.0" svgx:width="0.44,0.28,0.44,0.28,0.44,0.5,0.25,0.5,0.44,0.5,0.44,0.39,0.25,0.44,0.5,0.5,0.25,0.44,0.44,0.44,0.44,0.28,0.44,0.33,0.44,0.28,0.44,0.5,0.25,0.33,0.44,0.78,0.5,0.44,0.28,0.28,0.5,0.44,0.28,0.28,0.5,0.5,0.25,0.5,0.39,0.28,0.5,0.5,0.25,0.28,0.78,0.78,0.5,0.5,0.5,0.5,0.28,0.39,0.28,0.5,0.44,0.5,0.44,0.78,0.33" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">ciated genes and accelerated remyelination using immunohistochem-</text>
   <text y="488.909" x="62.359,64.681,68.002,70.324,73.141,76.876,78.946,80.638,84.958,90.241,94.732,97.549,102.373,108.196,114.019,115.711,119.527,123.847,128.167,129.859,133.675,135.997,139.813,143.629,145.951,148.768,153.088,157.408,159.1,165.922,168.244,172.06,174.877,179.197,182.518,186.334,190.654,194.974,197.296,201.112,202.804,206.125,208.447,212.767,217.087,219.409,223.225,226.546,228.616,230.308,235.627,239.947,244.267,248.587,251.908,256.228,259.045,262.861,264.553,268.873,271.69,273.382,280.204,284.524,287.341,289.663,293.983,297.979" svgx:width="0.28,0.39,0.28,0.33,0.5,0.25,0.25,0.5,0.67,0.61,0.33,0.56,0.67,0.67,0.25,0.44,0.5,0.5,0.25,0.44,0.28,0.44,0.44,0.28,0.33,0.5,0.5,0.25,0.78,0.28,0.44,0.33,0.5,0.39,0.44,0.5,0.5,0.28,0.44,0.25,0.39,0.28,0.5,0.5,0.28,0.44,0.39,0.25,0.25,0.61,0.5,0.5,0.5,0.39,0.5,0.33,0.44,0.25,0.5,0.33,0.25,0.78,0.5,0.33,0.28,0.5,0.44,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">istry, qRT-PCR and electron microscopic studies. Exposure of murine </text>
   <text y="499.907" x="62.359,66.679,69.001,71.323,75.643,79.963,84.283,88.099,92.419,96.739,99.556,103.876,107.692,112.012,114.334,118.15,121.471,123.721,126.034,128.356,132.676,134.926,137.239,139.561,143.881,147.697,149.947,152.26,156.076,160.396,167.218,171.538,175.858,180.178,184.498,188.818,191.068,193.381,195.703,200.023,203.839,206.656,210.472,214.288,217.609,221.425,225.745,227.995,230.308,234.628,238.948,243.268,246.589,250.909,255.229,259.549,262.366,266.686,269.008,272.824,275.146,277.468,281.788,286.108,288.358,290.671,294.991,297.988" svgx:width="0.5,0.28,0.28,0.5,0.5,0.5,0.44,0.5,0.5,0.33,0.5,0.44,0.5,0.28,0.44,0.39,0.25,0.55,0.28,0.5,0.25,0.55,0.28,0.5,0.44,0.25,0.55,0.44,0.5,0.78,0.5,0.5,0.5,0.5,0.5,0.25,0.55,0.28,0.5,0.44,0.33,0.44,0.44,0.39,0.44,0.5,0.25,0.55,0.5,0.5,0.5,0.39,0.5,0.5,0.5,0.33,0.5,0.28,0.44,0.28,0.28,0.5,0.5,0.25,0.55,0.5,0.33,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">oligodendrocytes to the compound increased phosphorylation of </text>
   <text y="510.905" x="62.359,66.679,70.495,72.817,76.633,79.45,83.266,87.082,89.404,93.22,97.54,99.862,104.182,106.405,110.221,112.543,114.766,118.087,121.903,124.72,127.042,131.362,135.178,138.499,140.722,145.042,149.362,151.432,153.655,157.975,162.295,164.518,168.838,173.158,177.478,179.701,184.021,188.341,190.564,194.38,197.701,199.924,203.245,207.565,211.885,218.203,222.523,224.746,227.068,231.388,233.449,241.045,244.861,248.182,250.504,254.32,257.137,261.457,263.68,268.0,270.322,274.642,276.964,280.285,282.355,284.416,289.735,294.055,298.051" svgx:width="0.5,0.44,0.28,0.44,0.33,0.44,0.44,0.28,0.44,0.5,0.28,0.5,0.25,0.44,0.28,0.25,0.39,0.44,0.33,0.28,0.5,0.44,0.39,0.25,0.5,0.5,0.25,0.25,0.5,0.5,0.25,0.5,0.5,0.5,0.25,0.5,0.5,0.25,0.44,0.39,0.25,0.39,0.5,0.5,0.72,0.5,0.25,0.28,0.5,0.25,0.94,0.44,0.39,0.28,0.44,0.33,0.5,0.25,0.5,0.28,0.5,0.28,0.39,0.25,0.25,0.61,0.5,0.44,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">beta-catenin at serines 33, 35 und 37 as shown in Western blots. The </text>
   <text y="521.903" x="62.359,66.679,70.999,74.32,76.642,78.964,81.286,85.606,89.422,91.627,95.443,98.098,100.915,104.731,108.547,110.869,113.074,117.394,120.211,122.416,124.738,129.058,132.874,135.079,141.397,146.221,152.539,155.356,161.674,163.879,168.199,172.519,174.724,179.044,181.366,183.688,188.008,192.328,196.648,200.464,204.784,209.104,211.921,216.241,220.561,222.883,225.205,229.021,231.343,233.548,237.868,240.19,242.845,245.662,249.478,252.295,256.111,260.431,262.753,265.075,268.891,271.213,273.535,277.855,282.175,284.38,290.698,294.514,298.015" svgx:width="0.5,0.5,0.39,0.28,0.28,0.28,0.5,0.44,0.25,0.44,0.33,0.33,0.44,0.44,0.28,0.25,0.5,0.33,0.25,0.28,0.5,0.44,0.25,0.72,0.56,0.72,0.33,0.72,0.25,0.5,0.5,0.25,0.5,0.28,0.28,0.5,0.5,0.5,0.44,0.5,0.5,0.33,0.5,0.5,0.28,0.28,0.44,0.28,0.25,0.5,0.28,0.33,0.33,0.44,0.33,0.44,0.5,0.28,0.28,0.44,0.28,0.28,0.5,0.5,0.25,0.72,0.44,0.39,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">positive effect of the NSAID on oligodendroglial differentiation was </text>
   <text y="532.901" x="62.359,66.175,70.495,73.312,77.632,81.952,85.768,88.09,91.906,96.226,98.476,99.421,103.741,107.062,109.384,113.704,118.024,120.274,121.219,123.541,127.861,132.181,134.503,138.823,141.145,143.467,147.787,150.604,153.925,156.175,157.12,161.44,164.257,166.507,167.452,171.772,174.094,178.414,182.23,186.55,190.87,194.686,199.006,201.256,202.201,205.522,209.842,214.162,216.484,220.804,224.62,226.942,230.758,234.079,237.895,240.145,241.09,245.41,247.66,248.605,252.925,256.741,259.063,262.879,265.129,266.074,268.891,275.209,280.033,286.351,290.671,294.991,297.988" svgx:width="0.44,0.5,0.33,0.5,0.5,0.44,0.28,0.44,0.5,0.25,0.55,0.5,0.39,0.28,0.5,0.5,0.25,0.55,0.28,0.5,0.5,0.28,0.5,0.28,0.28,0.5,0.33,0.39,0.25,0.55,0.5,0.33,0.25,0.55,0.5,0.28,0.5,0.44,0.5,0.5,0.44,0.5,0.25,0.55,0.39,0.5,0.5,0.28,0.5,0.44,0.28,0.44,0.39,0.44,0.25,0.55,0.5,0.25,0.55,0.5,0.44,0.28,0.44,0.25,0.55,0.33,0.72,0.56,0.72,0.5,0.5,0.33,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">abrogated using inhibitors of glycogen synthetase 3 beta (GSK3b) </text>
   <text y="543.899" x="62.359,64.681,69.001,72.817,75.139,76.966,79.288,82.609,84.436,88.756,92.572,95.389,97.711,99.538,103.858,106.675,108.502,110.824,115.144,118.96,120.787,125.107,128.923,131.245,135.061,137.878,141.694,145.51,147.832,151.648,155.968,158.29,162.61,164.437,168.757,172.573,176.893,179.71,183.526,187.846,191.662,193.984,196.306,200.626,204.946,206.773,210.589,214.909,221.731,226.051,228.373,232.189,236.509,238.579,240.244,245.248,248.065,251.881,256.201,259.522,262.339,266.155,269.971,272.293,274.615,278.935,283.255,285.082,289.402,292.219,294.046,298.042" svgx:width="0.28,0.5,0.44,0.28,0.25,0.28,0.39,0.25,0.5,0.44,0.33,0.28,0.25,0.5,0.33,0.25,0.28,0.5,0.44,0.25,0.5,0.44,0.28,0.44,0.33,0.44,0.44,0.28,0.44,0.5,0.28,0.5,0.25,0.5,0.44,0.5,0.33,0.44,0.5,0.44,0.28,0.28,0.5,0.5,0.25,0.44,0.5,0.78,0.5,0.28,0.44,0.5,0.25,0.25,0.61,0.33,0.44,0.5,0.39,0.33,0.44,0.44,0.28,0.28,0.5,0.5,0.25,0.5,0.33,0.25,0.44,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">that is part of the beta-catenin degradation complex. Transfection of a </text>
   <text y="554.897" x="62.359,69.181,73.501,76.318,78.64,82.96,86.776,88.864,93.184,95.506,97.828,102.148,106.468,110.788,114.604,118.924,123.244,126.061,130.381,134.701,137.023,139.345,143.161,145.483,147.571,151.387,155.203,157.525,159.847,161.935,164.257,166.579,170.899,174.715,176.803,183.121,185.443,187.765,192.085,194.173,197.989,200.077,202.894,206.71,211.03,215.35,218.167,220.489,224.305,227.122,229.21,233.026,236.347,239.668,243.484,247.804,249.892,253.708,258.028,262.348,265.165,267.487,270.304,277.126,280.942,285.262,287.35,289.672,293.992,297.988" svgx:width="0.78,0.5,0.33,0.28,0.5,0.44,0.25,0.5,0.28,0.28,0.5,0.5,0.5,0.44,0.5,0.5,0.33,0.5,0.5,0.28,0.28,0.44,0.28,0.25,0.44,0.44,0.28,0.28,0.25,0.28,0.28,0.5,0.44,0.25,0.72,0.28,0.28,0.5,0.25,0.44,0.25,0.33,0.44,0.5,0.5,0.33,0.28,0.44,0.33,0.25,0.44,0.39,0.39,0.44,0.5,0.25,0.44,0.5,0.5,0.33,0.28,0.33,0.78,0.44,0.5,0.25,0.28,0.5,0.44,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">murine oligodendroglial cell line with a reporter assay confirmed the </text>
   <text y="565.895" x="62.359,66.679,70.999,77.317,81.637,84.454,88.27,92.59,96.91,99.232,103.048,105.37,107.692,112.012,116.332,118.582,121.129,125.449,128.266,130.516,133.063,135.385,139.705,143.521,145.771,148.156,156.472,160.792,163.114,165.436,169.756,173.572,175.894,179.71,182.527,186.343,190.159,192.481,196.297,200.617,202.939,207.259,209.509,212.056,215.377,217.699,222.019,226.339,230.155,232.477,234.799,239.119,243.439,245.689,248.236,252.556,256.372,258.694,263.014,269.332,273.148,277.468,279.718,282.265,286.081,288.898,291.22,295.036,298.033" svgx:width="0.5,0.5,0.72,0.5,0.33,0.44,0.5,0.5,0.28,0.44,0.28,0.28,0.5,0.5,0.25,0.55,0.5,0.33,0.25,0.55,0.28,0.5,0.44,0.25,0.55,0.94,0.5,0.28,0.28,0.5,0.44,0.28,0.44,0.33,0.44,0.44,0.28,0.44,0.5,0.28,0.5,0.25,0.55,0.39,0.28,0.5,0.5,0.44,0.28,0.28,0.5,0.5,0.25,0.55,0.5,0.44,0.28,0.5,0.72,0.44,0.5,0.25,0.55,0.44,0.33,0.28,0.44,0.33,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">downregulation of the Wnt/beta-catenin signaling pathway after </text>
   <text y="576.893" x="62.359,66.175,70.495,74.815,77.137,79.459,81.781,86.101,90.421,92.977,97.297,100.114,102.67,104.992,109.312,113.128,115.684,122.002,126.826,133.144,135.961,142.279,144.349,146.905,151.729,156.049,158.866,161.188,165.508,169.324,172.141,178.963,183.283,186.1,189.916,191.986,194.542,196.864,201.184,203.74,208.06,211.876,216.196,220.012,222.334,224.656,228.472,232.288,234.61,236.932,241.252,243.808,250.63,254.95,259.27,261.592,264.409,266.731,270.547,274.867,277.423,281.743,284.065,286.387,290.707,295.027" svgx:width="0.44,0.5,0.5,0.28,0.28,0.28,0.5,0.5,0.25,0.5,0.33,0.25,0.28,0.5,0.44,0.25,0.72,0.56,0.72,0.33,0.72,0.25,0.25,0.56,0.5,0.33,0.28,0.5,0.44,0.33,0.78,0.5,0.33,0.44,0.25,0.25,0.28,0.5,0.25,0.5,0.44,0.5,0.44,0.28,0.28,0.44,0.44,0.28,0.28,0.5,0.25,0.78,0.5,0.5,0.28,0.33,0.28,0.44,0.5,0.25,0.5,0.28,0.28,0.5,0.5,0.33" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">addition of the NSAID. Furthermore, in genetically modified oligo-</text>
   <text y="587.891" x="62.359,66.679,70.495,74.815,79.135,81.952,86.272,90.088,94.408,96.73,100.546,103.867,106.117,107.854,110.176,114.496,116.746,118.483,124.801,129.121,131.443,135.259,139.579,141.829,143.566,147.886,151.702,154.024,157.84,160.657,164.473,168.289,170.611,174.427,178.747,181.069,185.389,187.639,189.376,193.192,197.008,201.328,205.648,209.968,212.29,214.54,216.277,220.597,224.413,226.663,228.4,232.72,237.04,241.36,244.681,249.001,253.321,257.641,260.458,264.778,267.1,270.916,273.238,277.054,281.374,283.624,285.361,289.177,293.497,297.997" svgx:width="0.5,0.44,0.5,0.5,0.33,0.5,0.44,0.5,0.28,0.44,0.39,0.25,0.55,0.28,0.5,0.25,0.55,0.72,0.5,0.28,0.44,0.5,0.25,0.55,0.5,0.44,0.28,0.44,0.33,0.44,0.44,0.28,0.44,0.5,0.28,0.5,0.25,0.55,0.44,0.44,0.5,0.5,0.5,0.28,0.25,0.55,0.5,0.44,0.25,0.55,0.5,0.5,0.5,0.39,0.5,0.5,0.5,0.33,0.5,0.28,0.44,0.28,0.44,0.5,0.25,0.55,0.44,0.5,0.5,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">dendrocytes in which beta-catenin cannot be phosphorylated and </text>
   <text y="598.889" x="62.359,66.679,70.495,74.815,77.632,81.448,85.768,89.584,93.904,95.974,98.044,102.364,106.684,108.754,112.57,115.225,118.042,121.858,125.674,127.996,130.066,134.386,137.203,139.273,141.595,145.915,149.731,151.801,158.119,162.943,169.261,172.078,178.396,180.466,184.786,189.106,191.176,195.496,197.818,200.473,203.29,207.106,209.923,213.739,218.059,220.381,222.703,226.519,228.841,231.163,235.483,239.803,241.873,248.191,252.007,255.328,257.398,261.718,266.038,269.359,273.176,275.992,280.313,284.129,288.449" svgx:width="0.5,0.44,0.5,0.33,0.44,0.5,0.44,0.5,0.25,0.25,0.5,0.5,0.25,0.44,0.33,0.33,0.44,0.44,0.28,0.25,0.5,0.33,0.25,0.28,0.5,0.44,0.25,0.72,0.56,0.72,0.33,0.72,0.25,0.5,0.5,0.25,0.5,0.28,0.33,0.33,0.44,0.33,0.44,0.5,0.28,0.28,0.44,0.28,0.28,0.5,0.5,0.25,0.72,0.44,0.39,0.25,0.5,0.5,0.39,0.44,0.33,0.5,0.44,0.5,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">degraded, no effect of the NSAID on differentiation was observed.</text>
   <text y="609.887" x="62.359,68.812,73.267,78.226,82.177,84.634,89.593,93.049,95.506,99.961,104.92,108.376,111.328" svgx:width="0.72,0.5,0.56,0.44,0.28,0.56,0.39,0.28,0.5,0.56,0.39,0.33,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPS-BoldMT;font-size:9.0px;stroke:none;">Conclusions: </text>
   <text y="609.887" x="113.65,119.104,123.559,127.51,129.832,136.285,141.244,147.697,150.649,157.102,159.424,163.879,166.831,171.286,178.243,182.698,185.155,189.106,192.562,194.884,199.339,201.796,204.586,207.538,211.489,214.441,218.392,222.847,225.304,227.761,231.712,234.169,236.626,241.081,245.536,247.858,252.313,255.265,257.587,264.544,268.999,271.951,274.408,278.863,282.814,285.127,289.078,293.533,298.033" svgx:width="0.61,0.5,0.44,0.25,0.72,0.56,0.72,0.33,0.72,0.25,0.5,0.33,0.5,0.78,0.5,0.28,0.44,0.39,0.25,0.5,0.28,0.33,0.33,0.44,0.33,0.44,0.5,0.28,0.28,0.44,0.28,0.28,0.5,0.5,0.25,0.5,0.33,0.25,0.78,0.5,0.33,0.28,0.5,0.44,0.25,0.44,0.5,0.5,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">The NSAID promotes differentiation of murine and </text>
   <text y="620.885" x="62.359,66.814,71.269,78.226,82.177,86.632,88.954,93.409,95.866,98.323,102.778,107.233,111.688,115.639,120.094,124.549,127.501,131.956,135.907,140.362,142.819,146.77,150.226" svgx:width="0.5,0.5,0.78,0.44,0.5,0.25,0.5,0.28,0.28,0.5,0.5,0.5,0.44,0.5,0.5,0.33,0.5,0.44,0.5,0.28,0.44,0.39,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">human oligodendrocytes </text>
   <text y="620.885" x="152.548,155.005,159.46,161.773,165.724,168.181,170.638,173.761,178.216" svgx:width="0.28,0.5,0.25,0.44,0.28,0.28,0.39,0.5,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPS-ItalicMT;font-size:9.0px;stroke:none;">in vitro </text>
   <text y="620.885" x="180.529,184.48,188.935,193.39,195.712,199.663,204.118,208.573,212.524,216.979,220.93,224.881,228.337,230.659,233.611,237.562,244.519,248.974,252.925,255.382,257.839,262.294,266.245,268.702,271.159,275.614,280.069,282.526,284.848,287.8,292.255,295.018" svgx:width="0.44,0.5,0.5,0.25,0.44,0.5,0.5,0.44,0.5,0.44,0.44,0.39,0.25,0.33,0.44,0.78,0.5,0.44,0.28,0.28,0.5,0.44,0.28,0.28,0.5,0.5,0.28,0.25,0.33,0.5,0.33,0.33" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">and enhances remyelination; fur-</text>
   <text y="631.883" x="62.359,64.816,69.271,73.222,76.174,83.131,87.586,90.538,94.489,96.739,97.729,102.184,106.639,109.591,111.841,112.831,115.783,119.734,123.19,127.645,130.102,132.559,136.015,138.265,139.255,142.711,147.166,151.621,156.076,160.027,163.483,165.94,168.19,169.18,171.637,176.092,180.043,182.5,184.75,185.74,188.197,192.652,196.603,200.059,204.01,206.26,207.25,211.201,213.991,216.943,220.894,224.845,227.302,230.758,233.008,233.998,237.949,240.901,244.852,247.102,248.092,252.043,254.5,256.75,257.74,260.197,264.148,268.099,271.555,274.012,276.262,277.252,281.707,285.658,288.61,291.067,293.524,298.024" svgx:width="0.28,0.5,0.44,0.33,0.78,0.5,0.33,0.44,0.25,0.55,0.5,0.5,0.33,0.25,0.55,0.33,0.44,0.39,0.5,0.28,0.28,0.39,0.25,0.55,0.39,0.5,0.5,0.5,0.44,0.39,0.28,0.25,0.55,0.28,0.5,0.44,0.28,0.25,0.55,0.28,0.5,0.44,0.39,0.44,0.25,0.55,0.44,0.33,0.33,0.44,0.44,0.28,0.39,0.25,0.55,0.44,0.33,0.44,0.25,0.55,0.44,0.28,0.25,0.55,0.28,0.44,0.44,0.39,0.28,0.25,0.55,0.5,0.44,0.33,0.28,0.28,0.5,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">thermore our results suggest that these effects are at least partly </text>
   <text y="642.881" x="62.359,69.316,73.267,77.722,80.179,84.13,86.587,90.538,94.993,97.324,101.779,106.234,108.565,112.516,116.467,118.924,121.381,125.836,129.787,132.244,134.701,139.156,143.611,145.942,150.397,153.349,155.68,162.133,167.092,173.545,178.0,182.455,186.406,188.863,192.814,195.145,199.096,203.551,208.006,210.337,212.794,217.249,221.2,224.152,228.103,232.054,235.51,239.461,243.916,246.247,250.702,254.653,259.108,262.06,266.011,270.466,274.417,276.874,279.331,283.786,288.241,290.572,295.027,298.024" svgx:width="0.78,0.44,0.5,0.28,0.44,0.28,0.44,0.5,0.25,0.5,0.5,0.25,0.44,0.44,0.28,0.28,0.5,0.44,0.28,0.28,0.5,0.5,0.25,0.5,0.33,0.25,0.72,0.56,0.72,0.5,0.5,0.44,0.28,0.44,0.25,0.44,0.5,0.5,0.25,0.28,0.5,0.44,0.33,0.44,0.44,0.39,0.44,0.5,0.25,0.5,0.44,0.5,0.33,0.44,0.5,0.44,0.28,0.28,0.5,0.5,0.25,0.5,0.33,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">mediated by activation of GSK3beta and increased degradation of </text>
   <text y="653.879" x="62.359,66.814,70.765,73.222,77.173,80.125,84.076,88.027,90.484,94.435,98.89,101.347,105.802" svgx:width="0.5,0.44,0.28,0.44,0.33,0.44,0.44,0.28,0.44,0.5,0.28,0.5,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">beta-catenin.</text>
   <text y="675.875" x="62.359,67.858,72.358,76.858" svgx:width="0.61,0.5,0.5,0.5" style="fill:rgb(0,0,0);font-family:TimesNewRomanPS-BoldMT;font-size:9.0px;stroke:none;">P726</text>
   <text y="686.873" x="62.359,68.362,73.366,77.362,79.612,83.608,86.605,89.602,93.598,97.594,100.591,104.092,106.342,110.842,113.839,116.089,123.091,128.095,135.097,139.597,144.097,148.597,153.097,157.597,162.097,164.347,168.847,173.851,176.101,178.603,182.599,186.1,188.602,193.102,198.106,200.356,204.352,208.348,215.845,220.345,224.341,226.843,229.345,234.349,238.849,241.846,244.348,248.848,253.852,256.102,258.604,263.608,265.858,270.358" svgx:width="0.67,0.56,0.44,0.25,0.44,0.33,0.33,0.44,0.44,0.33,0.39,0.25,0.5,0.33,0.25,0.78,0.56,0.78,0.5,0.5,0.5,0.5,0.5,0.5,0.25,0.5,0.56,0.25,0.28,0.44,0.39,0.28,0.5,0.56,0.25,0.44,0.44,0.83,0.5,0.44,0.28,0.28,0.56,0.5,0.33,0.28,0.5,0.56,0.25,0.28,0.56,0.25,0.5,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPS-BoldMT;font-size:9.0px;stroke:none;">The effects of GSK239512 on lesion remyelination in a </text>
   <text y="697.871" x="62.359,66.355,70.351,72.853,77.353,82.357,85.858,88.36,93.364,97.864,100.114,104.11,108.106,115.603,118.105,121.102,124.099,126.601,131.605,136.105,138.355,146.851,151.855,154.105,159.109,163.609,168.613,173.617,176.119,180.619,183.616,186.118,190.618,195.622,198.619,200.869,205.873,209.869,213.37,215.872,220.372,225.376,227.626,232.126,235.123,237.373,241.873,244.123,249.127,254.131,258.631,262.132,266.128,268.378,272.878,277.378" svgx:width="0.44,0.44,0.28,0.5,0.56,0.39,0.28,0.56,0.5,0.25,0.44,0.44,0.83,0.28,0.33,0.33,0.28,0.56,0.5,0.25,0.94,0.56,0.25,0.56,0.5,0.56,0.56,0.28,0.5,0.33,0.28,0.5,0.56,0.33,0.25,0.56,0.44,0.39,0.28,0.5,0.56,0.25,0.5,0.33,0.25,0.5,0.25,0.56,0.56,0.5,0.39,0.44,0.25,0.5,0.5,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPS-BoldMT;font-size:9.0px;stroke:none;">relapsing remitting MS population: design of a phase 2a </text>
   <text y="708.869" x="62.359,64.861,72.358,76.858,81.358,83.86,88.864,93.364,95.614,99.115,102.112,107.116,112.12" svgx:width="0.28,0.83,0.5,0.5,0.28,0.56,0.5,0.25,0.39,0.33,0.56,0.56,0.5" style="fill:rgb(0,0,0);font-family:TimesNewRomanPS-BoldMT;font-size:9.0px;stroke:none;">imaging study</text>
   <text y="719.867" x="62.359,68.362,70.612,75.616,79.612,84.112,90.61,94.606,97.603,100.105,104.101,108.601,112.597,116.593" svgx:width="0.67,0.25,0.56,0.44,0.5,0.72,0.44,0.33,0.28,0.44,0.5,0.44,0.44,0.5" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">C Schwartzbach</text>
   <text y="717.439" x="121.095" svgx:width="0.5" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:5.85px;stroke:none;">1</text>
   <text y="719.959" x="124.02,126.27,128.52,134.523,136.773,143.271,146.268,150.768,155.268" svgx:width="0.25,0.25,0.67,0.25,0.72,0.33,0.5,0.5,0.44" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">, R Grove</text>
   <text y="717.439" x="159.264" svgx:width="0.5" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:5.85px;stroke:none;">2</text>
   <text y="719.959" x="162.189,164.439,166.689,171.693,173.943,179.442,183.942,188.442,195.444,199.944,203.445,207.945" svgx:width="0.25,0.25,0.56,0.25,0.61,0.5,0.5,0.78,0.5,0.39,0.5,0.5" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">, P Thompson</text>
   <text y="717.439" x="212.445" svgx:width="0.5" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:5.85px;stroke:none;">3</text>
   <text y="719.959" x="215.37,217.62,219.87,226.368,228.618,235.116,238.113,242.109,245.106" svgx:width="0.25,0.25,0.72,0.25,0.72,0.33,0.44,0.33,0.33" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">, O Graff</text>
   <text y="717.439" x="248.102" svgx:width="0.5" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:5.85px;stroke:none;">1</text>
   <text y="719.959" x="251.027,253.277,255.527,263.528,270.026" svgx:width="0.25,0.25,0.89,0.72,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">, MA </text>
   <text y="730.957" x="62.36,67.364,71.36,75.86,80.36,84.356,91.358,93.86,97.856" svgx:width="0.56,0.44,0.5,0.5,0.44,0.78,0.28,0.44,0.5" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">Peykamian</text>
   <text y="728.439" x="102.358" svgx:width="0.5" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:5.85px;stroke:none;">1</text>
   <text y="730.959" x="105.283,107.533,109.783,116.281,118.531,125.029,129.025,132.022,136.522,139.024,143.524" svgx:width="0.25,0.25,0.72,0.25,0.72,0.44,0.33,0.5,0.28,0.5,0.5" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">, K Harding</text>
   <text y="728.439" x="148.023" svgx:width="0.5" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:5.85px;stroke:none;">1</text>
   <text y="730.959" x="150.948,153.198,155.448,158.949,161.199,167.697,170.199,172.701,177.201,181.197,184.194" svgx:width="0.25,0.25,0.39,0.25,0.72,0.28,0.28,0.5,0.44,0.33,0.28" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">, J Hilpert</text>
   <text y="728.439" x="186.696" svgx:width="0.5" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:5.85px;stroke:none;">4</text>
   <text y="730.959" x="189.621,191.871,194.121,200.124,202.374,208.377,211.374,215.874,222.372" svgx:width="0.25,0.25,0.67,0.25,0.67,0.33,0.5,0.72,0.5" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">, R Brown</text>
   <text y="728.439" x="226.872" svgx:width="0.5" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:5.85px;stroke:none;">5</text>
   <text y="730.959" x="229.797,232.047,234.297,240.795,243.045,249.543,252.54,257.04,261.54,264.042" svgx:width="0.25,0.25,0.72,0.25,0.72,0.33,0.5,0.5,0.28,0.5" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">, D Arnold</text>
   <text y="728.439" x="268.541" svgx:width="0.5" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:5.85px;stroke:none;">5</text>
  </g>
  <path style="fill:none;stroke:rgb(0,0,0);stroke-width:0.44;" d="M310.020 672.310 L338.760 672.310 "/>
  <g begin="text">
   <text y="74.592" x="310.016" svgx:width="0.5" style="fill:rgb(0,0,0);font-family:TimesNewRomanPS-ItalicMT;font-size:5.85px;stroke:none;">1</text>
   <text y="77.112" x="312.941,319.439,321.941,326.441,330.437,334.937,339.437,345.935,348.437,350.939,355.439,361.442,363.944,366.446,370.946,374.942,377.192,379.442,384.941,388.937,392.438,396.434,400.934,404.435,408.431,412.931,415.181,420.185,423.686,426.188,430.688,435.188,439.688,442.19,446.186,448.436,453.935,458.435,461.936,465.932,468.182,470.432,476.435,482.438,484.688" svgx:width="0.72,0.28,0.5,0.44,0.5,0.5,0.72,0.28,0.28,0.5,0.67,0.28,0.28,0.5,0.44,0.25,0.25,0.61,0.44,0.39,0.44,0.5,0.39,0.44,0.5,0.25,0.56,0.39,0.28,0.5,0.5,0.5,0.28,0.44,0.25,0.61,0.5,0.39,0.44,0.25,0.25,0.67,0.67,0.25,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPS-ItalicMT;font-size:9.0px;stroke:none;">GlaxoSmithKline, Research Triangle Park, NC, </text>
   <text y="88.11" x="310.016,316.514,321.014,323.516,326.018,330.014,334.514,336.764,341.264,343.766,348.266,350.768,354.764,358.265,360.515" svgx:width="0.72,0.5,0.28,0.28,0.44,0.5,0.25,0.5,0.28,0.5,0.28,0.44,0.39,0.25,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPS-ItalicMT;font-size:9.0px;stroke:none;">United States, </text>
   <text y="85.592" x="362.764" svgx:width="0.5" style="fill:rgb(0,0,0);font-family:TimesNewRomanPS-ItalicMT;font-size:5.85px;stroke:none;">2</text>
   <text y="88.112" x="365.689,372.187,374.689,379.189,383.185,387.685,392.185,398.683,401.185,403.687,408.187,414.19,416.692,419.194,423.694,427.69,429.94,432.19,436.69,439.192,443.692,447.688,451.684,454.186,458.182,462.178,464.428,469.927,474.427,477.928,481.924,484.174,486.424,492.922,497.422,499.924,502.426,506.422,510.922" svgx:width="0.72,0.28,0.5,0.44,0.5,0.5,0.72,0.28,0.28,0.5,0.67,0.28,0.28,0.5,0.44,0.25,0.25,0.5,0.28,0.5,0.44,0.44,0.28,0.44,0.44,0.25,0.61,0.5,0.39,0.44,0.25,0.25,0.72,0.5,0.28,0.28,0.44,0.5,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPS-ItalicMT;font-size:9.0px;stroke:none;">GlaxoSmithKline, Stockley Park, United </text>
   <text y="99.11" x="310.015,316.018,318.52,323.02,327.52,332.02,336.52,343.018,345.268" svgx:width="0.67,0.28,0.5,0.5,0.5,0.5,0.72,0.25,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPS-ItalicMT;font-size:9.0px;stroke:none;">Kingdom, </text>
   <text y="96.592" x="347.519" svgx:width="0.5" style="fill:rgb(0,0,0);font-family:TimesNewRomanPS-ItalicMT;font-size:5.85px;stroke:none;">3</text>
   <text y="99.112" x="350.444,356.941,359.444,363.944,367.94,372.44,376.94,383.438,385.94,388.442,392.942,398.945,401.447,403.949,408.449,412.445,414.695,416.945,421.445,423.947,427.943,431.939,435.935,440.435,444.935,449.435,453.431,455.681,457.931,464.429,468.929,471.431,473.933,477.929,482.429,484.679,490.682,493.184,497.684,502.184,506.684,511.184,517.682,519.932" svgx:width="0.72,0.28,0.5,0.44,0.5,0.5,0.72,0.28,0.28,0.5,0.67,0.28,0.28,0.5,0.44,0.25,0.25,0.5,0.28,0.44,0.44,0.44,0.5,0.5,0.5,0.44,0.25,0.25,0.72,0.5,0.28,0.28,0.44,0.5,0.25,0.67,0.28,0.5,0.5,0.5,0.5,0.72,0.25,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPS-ItalicMT;font-size:9.0px;stroke:none;">GlaxoSmithKline, Stevenage, United Kingdom, </text>
   <text y="107.592" x="310.016" svgx:width="0.5" style="fill:rgb(0,0,0);font-family:TimesNewRomanPS-ItalicMT;font-size:5.85px;stroke:none;">4</text>
   <text y="110.112" x="312.941,319.439,321.941,326.441,330.437,334.937,339.437,345.935,348.437,350.939,355.439,361.442,363.944,366.446,370.946,374.942,377.192,379.442,383.942,388.442,392.942,397.442,401.942,406.442,410.942,413.444,415.694,417.944,423.947,428.447,430.949,435.449,439.949,442.199" svgx:width="0.72,0.28,0.5,0.44,0.5,0.5,0.72,0.28,0.28,0.5,0.67,0.28,0.28,0.5,0.44,0.25,0.25,0.5,0.5,0.5,0.5,0.5,0.5,0.5,0.28,0.25,0.25,0.67,0.5,0.28,0.5,0.5,0.25,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPS-ItalicMT;font-size:9.0px;stroke:none;">GlaxoSmithKline, Shanghai, China, </text>
   <text y="107.592" x="444.448" svgx:width="0.5" style="fill:rgb(0,0,0);font-family:TimesNewRomanPS-ItalicMT;font-size:5.85px;stroke:none;">5</text>
   <text y="110.112" x="447.373,453.376,457.372,461.872,465.373,469.873,475.372,479.368,481.618,487.117,491.113,494.614,498.61,503.11,506.611,510.607,515.107,517.357" svgx:width="0.67,0.44,0.5,0.39,0.5,0.61,0.44,0.25,0.61,0.44,0.39,0.44,0.5,0.39,0.44,0.5,0.25,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPS-ItalicMT;font-size:9.0px;stroke:none;">NeuroRx Research, </text>
   <text y="121.11" x="310.015,317.512,322.012,326.512,329.014,332.515,336.511,341.011,343.513,345.763,348.013,354.511,360.514,362.764,365.014,371.017,375.517,380.017,384.517,389.017" svgx:width="0.83,0.5,0.5,0.28,0.39,0.44,0.5,0.28,0.25,0.25,0.72,0.67,0.25,0.25,0.67,0.5,0.5,0.5,0.5,0.5" style="fill:rgb(0,0,0);font-family:TimesNewRomanPS-ItalicMT;font-size:9.0px;stroke:none;">Montreal, QC, Canada</text>
   <text y="148.11" x="310.015,316.018,320.518,324.514,329.518,334.018,337.852,342.352,347.356,352.36,357.364,360.361" svgx:width="0.67,0.5,0.44,0.56,0.5,0.44,0.5,0.56,0.56,0.56,0.33,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPS-BoldMT;font-size:9.0px;stroke:none;">Background: </text>
   <text y="148.11" x="363.052,369.55,374.554,381.052,385.552,390.052,394.552,399.052,403.552,408.052,410.743,413.245,416.746,419.437,423.433,426.124,430.624,435.124,437.626,441.622,446.122,448.624,450.874,453.565,457.066,461.062,463.564,467.56,471.556,474.058,476.56,481.06,485.056,487.306,489.997,494.497,497.494,501.49,503.992,506.494,510.994,513.685,518.185,520.687,525.187,529.183,533.683,537.679,540.181,542.683" svgx:width="0.72,0.56,0.72,0.5,0.5,0.5,0.5,0.5,0.5,0.25,0.28,0.39,0.25,0.44,0.25,0.5,0.5,0.28,0.44,0.5,0.28,0.25,0.25,0.39,0.44,0.28,0.44,0.44,0.28,0.28,0.5,0.44,0.25,0.25,0.5,0.33,0.44,0.28,0.28,0.5,0.25,0.5,0.28,0.5,0.44,0.5,0.44,0.28,0.28,0.33" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">GSK239512 is a potent, selective, orally bioavail-</text>
   <text y="159.108" x="310.015,314.011,318.511,321.013,325.009,327.259,328.033,332.029,336.529,341.029,343.279,344.053,348.553,351.55,355.546,358.048,362.548,364.798,365.572,370.072,374.068,378.568,382.564,385.066,388.063,392.059,396.559,399.061,401.311,402.085,406.585,409.087,412.588,415.09,419.086,426.088,428.59,433.09,437.086,439.336,440.11,444.61,446.86,447.634,450.631,454.627,458.623,462.619,467.119,469.621,474.121,477.118,479.368,480.142,483.139,489.637,494.137,500.14,503.137,505.387,506.161,510.157,514.657,517.159,521.155,525.655,530.155,534.655,537.157,540.658,543.16" svgx:width="0.44,0.5,0.28,0.44,0.25,0.55,0.44,0.5,0.5,0.25,0.55,0.5,0.33,0.44,0.28,0.5,0.25,0.55,0.5,0.44,0.5,0.44,0.28,0.33,0.44,0.5,0.28,0.25,0.55,0.5,0.28,0.39,0.28,0.44,0.78,0.28,0.5,0.44,0.25,0.55,0.5,0.25,0.55,0.33,0.44,0.44,0.44,0.5,0.28,0.5,0.33,0.25,0.55,0.33,0.72,0.5,0.67,0.33,0.25,0.55,0.44,0.5,0.28,0.44,0.5,0.5,0.5,0.28,0.39,0.28,0.28" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">able and brain penetrant histamine 3 receptor (H3R) antagonist/</text>
   <text y="170.106" x="310.015,312.517,317.017,321.517,325.513,328.51,332.011,336.007,338.257,338.968,342.964,347.464,351.964,356.464,358.966,362.467,364.969,367.219,369.469,370.18,373.177,377.677,379.927,380.647,388.648,393.652,395.902,398.152,398.863,402.859,407.359,409.861,414.361,418.357,422.857,426.853,430.849,433.099,433.81,437.311,441.811,446.311,450.811,455.311,458.308,460.81,464.311,466.561,467.272,471.268,473.518,474.238,477.235,481.231,483.733,486.235,490.735,493.732,497.728,499.978,500.689,505.189,508.186,510.436,511.147,515.647,518.149,520.651,525.151,529.651,534.151,538.147,542.647" svgx:width="0.28,0.5,0.5,0.44,0.33,0.39,0.44,0.25,0.55,0.44,0.5,0.5,0.5,0.28,0.39,0.28,0.25,0.25,0.55,0.33,0.5,0.25,0.55,0.89,0.56,0.25,0.25,0.55,0.44,0.5,0.28,0.5,0.44,0.5,0.44,0.44,0.25,0.55,0.39,0.5,0.5,0.5,0.5,0.33,0.28,0.39,0.25,0.55,0.44,0.25,0.55,0.33,0.44,0.28,0.28,0.5,0.33,0.44,0.25,0.55,0.5,0.33,0.25,0.55,0.5,0.28,0.28,0.5,0.5,0.5,0.44,0.5,0.33" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">inverse agonist. In MS, evidence supports a failure of oligoden-</text>
   <text y="181.104" x="310.015,314.515,317.512,322.012,326.008,330.508,333.01,337.006,339.544,344.044,347.041,351.037,355.033,359.533,362.53,366.031,370.531,373.528,376.066,380.062,384.058,386.56,389.062,392.563,395.101,398.098,404.596,409.6,415.603,418.6,421.138,425.638,428.14,430.975,433.972,437.968,440.965,444.961,449.461,451.963,454.465,458.461,460.963,463.465,467.965,472.465,475.003,478.999,482.5,485.038,487.54,492.04,496.036,498.574,501.571,506.071,510.571,513.073,515.611,519.607,523.603,528.103,531.604,535.6,538.138,542.638,545.635" svgx:width="0.5,0.33,0.5,0.44,0.5,0.28,0.44,0.25,0.5,0.33,0.44,0.44,0.5,0.33,0.39,0.5,0.33,0.25,0.44,0.44,0.28,0.28,0.39,0.25,0.33,0.72,0.56,0.67,0.33,0.25,0.5,0.28,0.33,0.33,0.44,0.33,0.44,0.5,0.28,0.28,0.44,0.28,0.28,0.5,0.5,0.25,0.44,0.39,0.25,0.28,0.5,0.44,0.25,0.33,0.5,0.5,0.28,0.25,0.44,0.44,0.5,0.39,0.44,0.25,0.5,0.33,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">drocyte precursor cells (OPC) differentiation as the root cause of </text>
   <text y="192.102" x="310.015,313.012,317.008,324.01,328.51,332.506,335.008,337.51,342.01,346.006,348.508,351.01,355.51,360.01,362.26,365.59,368.587,372.583,375.085,377.587,382.087,385.084,389.08,391.33,393.58,396.919,401.923,404.92,408.916,412.912,415.414,417.916,422.416,424.918,428.914,432.91,435.412,437.662,440.992,444.493,446.995,451.495,455.995,458.497,462.493,465.994,468.244,471.583,476.083,480.079,487.081,491.581,496.081,499.582,502.084,505.081,509.077,511.579,514.081,518.581,523.081,525.331,528.661,535.159,539.659,545.662" svgx:width="0.33,0.44,0.78,0.5,0.44,0.28,0.28,0.5,0.44,0.28,0.28,0.5,0.5,0.25,0.55,0.33,0.44,0.28,0.28,0.5,0.33,0.44,0.25,0.25,0.55,0.56,0.33,0.44,0.44,0.28,0.28,0.5,0.28,0.44,0.44,0.28,0.25,0.55,0.39,0.28,0.5,0.5,0.28,0.44,0.39,0.25,0.55,0.5,0.44,0.78,0.5,0.5,0.39,0.28,0.33,0.44,0.28,0.28,0.5,0.5,0.25,0.55,0.72,0.5,0.67,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">remyelination failure. Preclinical studies demonstrating H3R </text>
   <text y="203.1" x="310.015,314.011,318.511,323.011,326.008,330.004,333.505,337.006,339.508,344.008,348.508,351.19,355.186,359.686,364.186,366.877,370.873,374.869,377.371,379.873,384.373,386.875,389.377,393.877,396.559,401.059,405.559,408.241,414.739,419.743,425.746,429.247,431.938,436.438,440.434,444.934,448.93,451.612,454.114,458.614,463.114,465.616,469.612,473.608,476.11,480.106,484.606,487.288,489.79,494.29,498.286,500.968,505.468,509.968,512.47,516.466,520.966,523.468,525.97,529.966,532.468,535.159,538.156,542.656,545.653" svgx:width="0.44,0.5,0.5,0.33,0.44,0.39,0.39,0.28,0.5,0.5,0.25,0.44,0.5,0.5,0.25,0.44,0.44,0.28,0.28,0.5,0.28,0.28,0.5,0.25,0.5,0.5,0.25,0.72,0.56,0.67,0.39,0.25,0.5,0.44,0.5,0.44,0.25,0.28,0.5,0.5,0.28,0.44,0.44,0.28,0.44,0.5,0.25,0.28,0.5,0.44,0.25,0.5,0.5,0.28,0.44,0.5,0.28,0.28,0.44,0.28,0.25,0.33,0.5,0.33,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">expression and activity on OPCs have indicated the potential for </text>
   <text y="214.098" x="310.015,314.515,318.511,323.011,327.007,329.509,334.009,338.509,345.511,349.507,354.007,356.509,358.759,363.259,366.256,368.506,375.004,380.008,386.506,391.006,395.506,400.006,404.506,409.006,413.506,415.756,418.258,422.758,425.008,433.009,438.013" svgx:width="0.5,0.44,0.5,0.44,0.28,0.5,0.5,0.78,0.44,0.5,0.28,0.25,0.5,0.33,0.25,0.72,0.56,0.72,0.5,0.5,0.5,0.5,0.5,0.5,0.25,0.28,0.5,0.25,0.89,0.56,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">development of GSK239512 in MS.</text>
   <text y="225.096" x="310.015,316.882,321.751,324.613,328.474,332.335,335.197,337.564,341.929,345.79,349.156,352.018" svgx:width="0.78,0.56,0.33,0.44,0.44,0.33,0.28,0.5,0.44,0.39,0.33,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPS-BoldMT;font-size:9.0px;stroke:none;">Objectives: </text>
   <text y="225.096" x="354.619,359.353,363.718,366.319,370.684,373.546,377.407,380.773,384.634,388.999,391.366,393.967,396.334,400.699,404.56,407.161,411.526,415.387,418.753,421.12,425.485,429.85,432.451,436.312,440.677,445.042,447.643,452.008,454.87,458.731,461.098,463.465,470.332,472.699,477.064,480.925,483.787,488.152,490.753,494.119,498.484,502.849,505.216,509.077,512.938,515.305,517.906,522.271,524.638,528.004,532.369,536.734,540.19,542.665" svgx:width="0.61,0.5,0.25,0.5,0.33,0.44,0.39,0.44,0.5,0.28,0.25,0.28,0.5,0.44,0.25,0.5,0.44,0.39,0.28,0.5,0.5,0.25,0.44,0.5,0.5,0.25,0.5,0.33,0.44,0.28,0.28,0.78,0.28,0.5,0.44,0.33,0.5,0.25,0.39,0.5,0.5,0.28,0.44,0.44,0.28,0.25,0.5,0.28,0.39,0.5,0.5,0.39,0.28,0.33" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">To present the design and preliminary subject disposi-</text>
   <text y="236.094" x="310.006,312.463,314.92,319.375,323.83,326.557,331.012,333.964,336.691,340.642,343.369,349.822,354.781,361.234,364.186,367.138,371.593,376.048,380.503,384.454,388.909,391.636,396.091,400.546,404.497,407.953,411.904,414.631,419.086,423.037,425.764,429.22,431.677,436.132,440.587,445.042,447.769,450.226,454.681,459.136,463.087,466.543,469.0,471.457,475.912,479.863,482.32,484.777,489.232,493.687,496.414,498.871,503.326,507.277,510.004,513.955,516.745,519.697,523.648,527.599,530.056,532.783,536.734,541.189,545.689" svgx:width="0.28,0.28,0.5,0.5,0.25,0.5,0.33,0.25,0.44,0.25,0.72,0.56,0.72,0.33,0.33,0.5,0.5,0.5,0.44,0.5,0.25,0.5,0.5,0.44,0.39,0.44,0.25,0.5,0.44,0.25,0.39,0.28,0.5,0.5,0.5,0.25,0.28,0.5,0.5,0.44,0.39,0.28,0.28,0.5,0.44,0.28,0.28,0.5,0.5,0.25,0.28,0.5,0.44,0.25,0.44,0.33,0.33,0.44,0.44,0.28,0.25,0.44,0.5,0.5,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">tion of a GSK-funded phase 2a study investigating the effect and </text>
   <text y="247.092" x="310.006,313.462,317.413,320.365,324.316,326.773,331.228,333.55,338.005,340.957,343.279,349.732,354.691,361.144,365.599,370.054,374.509,378.964,383.419,387.874,390.196,392.653,397.108,399.43,403.885,406.837,411.292,418.249,422.704,425.161,427.618,432.073,436.528,438.85,441.802,445.753,452.71,457.165,461.116,463.573,466.03,470.485,474.436,476.893,479.35,483.805,488.26,490.582,493.039,497.494,499.816,504.271,508.222,510.679,513.136,517.087,521.542,523.999,527.455,529.777,536.23,538.687,541.144,545.644" svgx:width="0.39,0.44,0.33,0.44,0.28,0.5,0.25,0.5,0.33,0.25,0.72,0.56,0.72,0.5,0.5,0.5,0.5,0.5,0.5,0.25,0.28,0.5,0.25,0.5,0.33,0.5,0.78,0.5,0.28,0.28,0.5,0.5,0.25,0.33,0.44,0.78,0.5,0.44,0.28,0.28,0.5,0.44,0.28,0.28,0.5,0.5,0.25,0.28,0.5,0.25,0.5,0.44,0.28,0.28,0.44,0.5,0.28,0.39,0.25,0.72,0.28,0.28,0.5,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">safety of GSK239512 in promoting remyelination in patients with </text>
   <text y="258.09" x="310.006,312.958,316.909,319.366,323.317,327.772,331.228,333.685,338.14,342.595,345.061,348.013,351.964,358.921,361.378,363.835,366.292,368.749,373.204,377.659,380.125,388.081,393.04,395.506,398.458,404.416,410.374,418.33,423.289,426.241,428.446,430.912,435.367,438.823,441.28,445.735,450.19,452.656,457.111,460.063,464.014,466.471,470.926,473.392,481.348,487.306,490.258,492.724,496.675,500.131,503.587,507.538,510.994,514.45,521.407,525.358,529.813,532.27,535.726,538.192,542.647,545.644" svgx:width="0.33,0.44,0.28,0.44,0.5,0.39,0.28,0.5,0.5,0.25,0.33,0.44,0.78,0.28,0.28,0.28,0.28,0.5,0.5,0.25,0.89,0.56,0.25,0.33,0.67,0.67,0.89,0.56,0.33,0.25,0.25,0.5,0.39,0.28,0.5,0.5,0.25,0.5,0.33,0.44,0.28,0.5,0.25,0.89,0.67,0.33,0.25,0.44,0.39,0.39,0.44,0.39,0.39,0.78,0.44,0.5,0.28,0.39,0.25,0.5,0.33,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">relapsing remitting MS (RRMS), using brain MRI assessments of </text>
   <text y="269.088" x="310.006,316.963,320.914,325.369,329.824,333.775,336.232,338.689,342.64,346.591,349.048,351.505,355.96,360.415,362.62,365.077,368.029,371.98,376.435,379.891,382.843,386.794,389.746,391.951,394.903,398.854,401.311,403.768,408.223,410.428,413.38,421.336,426.79,432.748,435.7,437.905,440.362,444.817,447.022,451.477,455.428,457.885,461.836,465.787,468.244,470.449,472.906,476.857,480.313,482.77,487.225,491.68,493.885,496.837,500.788,507.745,512.2,516.151,518.608,521.065,525.52,529.471,531.928,534.385,538.84,543.295" svgx:width="0.78,0.44,0.5,0.5,0.44,0.28,0.28,0.44,0.44,0.28,0.28,0.5,0.5,0.25,0.28,0.33,0.44,0.5,0.39,0.33,0.44,0.33,0.25,0.33,0.44,0.28,0.28,0.5,0.25,0.33,0.89,0.61,0.67,0.33,0.25,0.28,0.5,0.25,0.5,0.44,0.28,0.44,0.44,0.28,0.25,0.28,0.44,0.39,0.28,0.5,0.5,0.25,0.33,0.44,0.78,0.5,0.44,0.28,0.28,0.5,0.44,0.28,0.28,0.5,0.5,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">magnetization transfer ratio (MTR) to detect lesion remyelination.</text>
   <text y="280.086" x="310.006,318.457,322.408,325.36,330.319,334.774,339.733,343.189,346.141" svgx:width="0.94,0.44,0.33,0.56,0.5,0.56,0.39,0.33,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPS-BoldMT;font-size:9.0px;stroke:none;">Methods: </text>
   <text y="280.086" x="351.334,357.787,362.746,369.199,371.449,374.392,377.848,380.305,384.76,389.215,393.67,395.92,398.863,405.316,409.771,417.727,421.849,426.304,430.759,435.214,439.669,444.124,446.374,449.317,451.774,455.23,457.48,460.423,464.374,466.624,469.567,472.519,476.47,480.925,485.38,489.835,496.792,499.249,503.2,507.151,511.606,513.811,516.061,519.004,523.459,527.41,530.362,534.313,536.77,539.227,543.178,545.68" svgx:width="0.72,0.56,0.72,0.25,0.55,0.39,0.28,0.5,0.5,0.5,0.25,0.55,0.72,0.5,0.89,0.5,0.5,0.5,0.5,0.5,0.5,0.25,0.55,0.28,0.39,0.25,0.55,0.44,0.25,0.55,0.33,0.44,0.5,0.5,0.5,0.78,0.28,0.44,0.44,0.5,0.25,0.25,0.55,0.5,0.44,0.33,0.44,0.28,0.28,0.44,0.28,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">GSK study H3M116477 is a randomized, parallel </text>
   <text y="291.084" x="310.006,314.461,317.413,321.868,326.323,330.778,332.983,334.27,338.725,341.182,345.133,349.084,353.035,357.49,361.945,364.897,368.848,373.303,377.758,380.215,383.167,387.622,390.079,392.536,396.487,400.942,402.229,405.685,408.142,412.597,417.052,421.507,422.794,425.746,431.704,436.492,438.697,443.152,447.607,452.062,453.349,455.806,460.261,464.212,468.667,471.124,473.581,476.533,478.99,482.941,485.893,488.35,489.637,496.09,502.048,507.502,511.957,516.412,520.867,525.322,529.777,534.232,538.687,543.142,545.644" svgx:width="0.5,0.33,0.5,0.5,0.5,0.25,0.25,0.5,0.28,0.44,0.44,0.44,0.5,0.5,0.33,0.44,0.5,0.5,0.28,0.33,0.5,0.28,0.28,0.44,0.5,0.25,0.39,0.28,0.5,0.5,0.5,0.25,0.33,0.67,0.61,0.25,0.5,0.5,0.5,0.25,0.28,0.5,0.44,0.5,0.28,0.28,0.33,0.28,0.44,0.33,0.28,0.25,0.72,0.67,0.61,0.5,0.5,0.5,0.5,0.5,0.5,0.5,0.5,0.28,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">group, placebo-controlled study (CT.gov identifier: NCT01772199; </text>
   <text y="302.082" x="310.006,315.46,319.915,324.37,327.322,331.273,337.231,342.523,344.773,345.52,347.977,352.432,356.383,360.838,363.295,365.752,368.704,371.161,375.112,378.064,380.521,382.771,383.518,387.973,392.428,396.883,401.338,404.29,408.745,413.2,417.655,422.11,426.565,431.02,433.972,438.427,442.882,445.834,448.039,450.289,451.036,455.995,460.45,464.905,467.362,471.313,475.264,477.721,481.177,483.427,484.174,490.627,493.084,495.541,499.996,502.246,502.993,508.951,514.909,522.865,527.824,530.074,530.821,534.772,539.227,541.684,545.68" svgx:width="0.61,0.5,0.5,0.33,0.44,0.67,0.61,0.25,0.55,0.28,0.5,0.44,0.5,0.28,0.28,0.33,0.28,0.44,0.33,0.28,0.25,0.55,0.5,0.5,0.5,0.5,0.33,0.5,0.5,0.5,0.5,0.5,0.5,0.33,0.5,0.5,0.33,0.25,0.25,0.55,0.56,0.5,0.5,0.28,0.44,0.44,0.28,0.39,0.25,0.55,0.72,0.28,0.28,0.5,0.25,0.55,0.67,0.67,0.89,0.56,0.25,0.55,0.44,0.5,0.28,0.44,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">EudraCT identifier: 2012-003627-38). Subjects with RRMS able </text>
   <text y="313.08" x="310.006,312.463,316.918,319.78,326.737,330.688,333.145,337.6,340.057,344.008,346.465,350.92,353.782,357.238,359.695,363.646,368.101,370.558,374.509,377.371,381.826,385.777,389.728,394.183,398.638,401.59,406.045,410.5,414.955,419.41,422.272,424.729,427.681,431.632,435.583,438.04,444.997,448.948,453.403,455.86,458.722,461.674,466.57,471.025,473.887,478.342,482.293,486.244,489.196,492.058,496.513,499.465,501.922,506.377,509.329,512.191,514.648,519.103,521.965,525.916,530.371,533.323,537.778,540.235,542.692" svgx:width="0.28,0.5,0.25,0.78,0.44,0.28,0.5,0.28,0.44,0.28,0.5,0.25,0.39,0.28,0.44,0.5,0.28,0.44,0.25,0.5,0.44,0.44,0.5,0.5,0.33,0.5,0.5,0.5,0.5,0.25,0.28,0.33,0.44,0.44,0.28,0.78,0.44,0.5,0.28,0.25,0.33,0.55,0.5,0.25,0.5,0.44,0.44,0.33,0.25,0.5,0.33,0.28,0.5,0.33,0.25,0.28,0.5,0.25,0.44,0.5,0.33,0.5,0.28,0.28,0.33" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">to maintain stable background treatment (≥1 year prior to enroll-</text>
   <text y="324.078" x="310.006,316.963,320.914,325.369,327.826,330.778,333.028,337.537,343.99,346.447,348.904,353.359,355.609,360.118,364.069,366.526,368.983,373.438,377.389,380.341,382.591,386.605,392.392,396.847,401.302,405.757,409.708,414.163,416.413,420.922,423.874,426.826,431.281,433.738,437.689,440.641,443.593,447.544,450.496,454.951,459.406,462.358,466.813,470.764,473.221,477.172,481.627,485.578,488.53,490.78,495.289,499.744,502.696,504.946,509.455,515.413,519.868,524.323,528.274,532.729,537.184,541.639,545.635" svgx:width="0.78,0.44,0.5,0.28,0.33,0.25,0.55,0.72,0.28,0.28,0.5,0.25,0.55,0.44,0.28,0.28,0.5,0.44,0.33,0.25,0.55,0.72,0.5,0.5,0.5,0.44,0.5,0.25,0.55,0.33,0.33,0.5,0.28,0.44,0.33,0.33,0.44,0.33,0.5,0.5,0.33,0.5,0.44,0.28,0.44,0.5,0.44,0.33,0.25,0.55,0.5,0.33,0.25,0.55,0.67,0.5,0.5,0.44,0.5,0.5,0.5,0.44,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">ment) with either Avonex (Interferon-beta1a) or Copaxone </text>
   <text y="335.076" x="310.006,312.958,319.411,321.868,325.819,328.276,330.733,333.685,337.636,344.593,348.544,351.496,352.864,359.317,363.268,367.219,369.676,373.627,376.084,380.035,382.987,384.85,387.802,392.257,395.209,397.072,399.529,403.984,407.935,409.798,414.253,418.708,421.66,425.611,428.068,430.525,434.98,439.435,441.298,445.753,448.705,450.568,453.025,457.48,461.431,463.294,466.75,469.207,473.662,478.117,482.572,484.435,490.888,494.839,497.791,501.742,503.605,506.557,510.508,514.963,519.418,523.873,530.83,533.287,537.238,541.189,545.689" svgx:width="0.33,0.72,0.28,0.44,0.28,0.28,0.33,0.44,0.78,0.44,0.33,0.25,0.72,0.44,0.44,0.28,0.44,0.28,0.44,0.33,0.25,0.33,0.5,0.33,0.25,0.28,0.5,0.44,0.25,0.5,0.5,0.33,0.44,0.28,0.28,0.5,0.5,0.25,0.5,0.33,0.25,0.28,0.5,0.44,0.25,0.39,0.28,0.5,0.5,0.5,0.25,0.72,0.44,0.33,0.44,0.25,0.33,0.44,0.5,0.5,0.5,0.78,0.28,0.44,0.44,0.5,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">(Glatiramer Acetate) for the duration of the study were randomized </text>
   <text y="346.074" x="310.006,312.463,316.918,319.168,319.96,323.911,326.161,326.953,331.408,333.865,338.32,340.57,341.362,344.314,348.265,350.722,353.179,357.634,359.884,360.676,365.131,369.082,371.539,377.992,381.943,385.894,390.349,392.599,393.391,397.846,400.303,404.254,408.205,412.156,416.611,421.066,423.316,424.108,428.059,432.514,436.969,439.219,440.011,446.464,451.423,457.876,462.331,466.786,471.241,475.696,480.151,484.606,486.856,487.648,490.6,495.055,498.007,500.257,501.049,505.0,507.25,508.042,510.499,514.954,517.411,521.362,523.819,526.069,526.861,529.318,532.27,536.221,540.172,542.628" svgx:width="0.28,0.5,0.25,0.55,0.44,0.25,0.55,0.5,0.28,0.5,0.25,0.55,0.33,0.44,0.28,0.28,0.5,0.25,0.55,0.5,0.44,0.28,0.72,0.44,0.44,0.5,0.25,0.55,0.5,0.28,0.44,0.44,0.44,0.5,0.5,0.25,0.55,0.44,0.5,0.5,0.25,0.55,0.72,0.56,0.72,0.5,0.5,0.5,0.5,0.5,0.5,0.25,0.55,0.33,0.5,0.33,0.25,0.55,0.44,0.25,0.55,0.28,0.5,0.28,0.44,0.28,0.25,0.55,0.28,0.33,0.44,0.44,0.28,0.33" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">in a 1:1 ratio between placebo and GSK239512 for a total treat-</text>
   <text y="357.072" x="310.006,316.963,320.914,325.369,327.826,329.644,334.099,338.05,341.002,343.459,347.914,352.369,354.187,358.642,361.594,363.412,367.867,372.322,374.14,380.593,384.544,388.495,392.95,396.406,398.611,400.267,405.721,410.176,414.127,415.945,420.4,423.352,425.809,432.766,436.717,439.669,444.124,445.942,449.893,454.348,458.803,463.258,467.713,470.17,474.625,477.082,478.9,481.357,484.813,486.631,489.088,493.543,497.494,499.312,503.263,507.718,511.669,514.126,518.581,522.532,524.989,527.446,531.901,536.356,538.174,542.629,545.626" svgx:width="0.78,0.44,0.5,0.28,0.25,0.5,0.44,0.33,0.28,0.5,0.5,0.25,0.5,0.33,0.25,0.5,0.5,0.25,0.72,0.44,0.44,0.5,0.39,0.25,0.25,0.61,0.5,0.44,0.25,0.5,0.33,0.28,0.78,0.44,0.33,0.5,0.25,0.44,0.5,0.5,0.5,0.5,0.28,0.5,0.28,0.25,0.28,0.39,0.25,0.28,0.5,0.44,0.25,0.44,0.5,0.44,0.28,0.5,0.44,0.28,0.28,0.5,0.5,0.25,0.5,0.33,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">ment period of 48 weeks. The primary endpoint is the evaluation of </text>
   <text y="368.07" x="310.006,316.963,320.914,324.865,329.32,331.57,333.118,337.069,341.524,345.475,349.93,354.385,358.336,361.792,364.042,365.59,368.047,372.502,374.752,376.3,378.757,382.708,386.164,388.621,393.076,397.531,399.781,401.329,408.286,412.741,416.692,419.149,421.606,426.061,430.012,432.469,434.926,439.381,443.836,446.086,447.634,452.089,455.545,458.002,462.457,466.912,469.162,470.71,473.167,479.62,484.075,486.325,487.873,495.829,501.283,507.241,509.491,511.039,514.99,519.445,523.9,528.355,532.81,535.267,539.722,542.179,545.68" svgx:width="0.78,0.44,0.44,0.5,0.25,0.55,0.44,0.5,0.44,0.5,0.5,0.44,0.39,0.25,0.55,0.28,0.5,0.25,0.55,0.28,0.44,0.39,0.28,0.5,0.5,0.25,0.55,0.78,0.5,0.44,0.28,0.28,0.5,0.44,0.28,0.28,0.5,0.5,0.25,0.55,0.5,0.39,0.28,0.5,0.5,0.25,0.55,0.28,0.72,0.5,0.25,0.55,0.89,0.61,0.67,0.25,0.55,0.44,0.5,0.5,0.5,0.5,0.28,0.5,0.28,0.39,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">mean changes in lesion myelination using two MTR endpoints </text>
   <text y="379.068" x="310.006,313.957,318.412,325.369,329.824,333.775,336.727,339.184,343.639,348.094,350.299,354.754,357.211,361.162,365.113,369.064,373.519,377.974,380.179,382.636,387.091,389.296,395.749,400.708,407.161,411.616,416.071,420.526,424.981,429.436,433.891,436.096,438.553,441.505,445.456,449.407,451.864,455.815,460.27,462.475,465.931,470.386,474.841,477.298,481.249,485.2,487.657,491.113" svgx:width="0.44,0.5,0.78,0.5,0.44,0.33,0.28,0.5,0.5,0.25,0.5,0.28,0.44,0.44,0.44,0.5,0.5,0.25,0.28,0.5,0.25,0.72,0.56,0.72,0.5,0.5,0.5,0.5,0.5,0.5,0.25,0.28,0.33,0.44,0.44,0.28,0.44,0.5,0.25,0.39,0.5,0.5,0.28,0.44,0.44,0.28,0.39,0.28" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">comparing placebo to GSK239512 treated subjects:</text>
   <text y="396.069" x="324.01,328.51,331.507,333.757,342.01,348.508,352.504,359.002,361.252,362.926,369.424,373.42,377.92,382.42,384.922,387.424,391.924,394.426,398.926,405.928,408.178,409.852,413.848,418.348,422.848,426.844,431.344,435.34,439.336,443.836,446.086,447.76,450.757,457.255,461.755,467.254,470.251,472.501,474.175,476.677,480.673,484.174,486.676,491.176,495.676,497.926,499.6,507.601,513.1,519.103,521.353,523.027,527.527,530.029,532.864,535.861,539.857,542.665" svgx:width="0.5,0.33,0.25,0.55,0.72,0.44,0.72,0.25,0.55,0.72,0.44,0.5,0.5,0.28,0.28,0.5,0.28,0.5,0.78,0.25,0.55,0.44,0.5,0.5,0.44,0.5,0.44,0.44,0.5,0.25,0.55,0.33,0.72,0.5,0.61,0.33,0.25,0.55,0.28,0.44,0.39,0.28,0.5,0.5,0.25,0.55,0.89,0.61,0.67,0.25,0.55,0.5,0.28,0.33,0.33,0.44,0.33,0.33" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">1) New Gadolinium enhanced (GdE) lesion MTR differ-</text>
   <text y="407.067" x="342.01,346.006,350.506,354.502,358.498,361.999,363.817,366.814,370.81,374.806,377.308,379.81,384.31,387.307,391.303,393.805,397.801,402.301,404.119,406.621,411.121,412.939,415.936,419.932,422.929,426.925,429.922,433.918,438.418,442.414,446.41,448.228,451.729,455.725,459.721,464.221,467.218,469.036,472.033,475.03,479.53,486.532,488.35,492.85,496.846,499.843,504.343,507.34,511.336,513.154,517.15,521.65,526.15,530.146,534.646,538.642,542.638" svgx:width="0.44,0.5,0.44,0.44,0.39,0.25,0.33,0.44,0.44,0.28,0.28,0.5,0.33,0.44,0.28,0.44,0.5,0.25,0.28,0.5,0.25,0.33,0.44,0.33,0.44,0.33,0.44,0.5,0.44,0.44,0.25,0.39,0.44,0.44,0.5,0.33,0.25,0.33,0.33,0.5,0.78,0.25,0.5,0.44,0.33,0.5,0.33,0.44,0.25,0.44,0.5,0.5,0.44,0.5,0.44,0.44,0.33" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">ences (calibrated to reference scan) from before enhance-</text>
   <text y="418.065" x="342.01,349.012,353.008,357.508,360.01,362.26,365.104,367.606,372.106,374.356,377.2,380.701,383.203,387.199,391.699,394.201,398.197,400.447,403.291,406.288,410.284,414.28,418.78,423.28,427.276,430.273,434.773,437.023,439.867,442.864,447.805,452.305,454.555,457.399,464.401,468.901,473.401,475.903,480.403,483.904,486.154,488.998,493.498,497.998,501.499,504.001,506.251,509.095,513.595,517.591,524.089,526.339,529.183,535.681,540.181,545.68" svgx:width="0.78,0.44,0.5,0.28,0.25,0.55,0.28,0.5,0.25,0.55,0.39,0.28,0.44,0.5,0.28,0.44,0.25,0.55,0.33,0.44,0.44,0.5,0.5,0.44,0.33,0.5,0.25,0.55,0.33,0.55,0.5,0.25,0.55,0.78,0.5,0.5,0.28,0.5,0.39,0.25,0.55,0.5,0.5,0.39,0.28,0.25,0.55,0.5,0.44,0.72,0.25,0.55,0.72,0.5,0.61,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">ment to stable recovery (≥3 months post new GdE </text>
   <text y="429.063" x="342.01,344.512,348.508,352.009,354.511,359.011,363.511,366.508,368.758,371.008,375.004,379.504" svgx:width="0.28,0.44,0.39,0.28,0.5,0.5,0.33,0.25,0.25,0.44,0.5,0.5" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">lesion), and</text>
   <text y="440.061" x="324.01,328.285,331.057,333.307,342.01,348.283,352.054,358.327,360.694,366.967,370.738,373.015,375.292,379.063,381.43,389.206,394.48,400.258,402.625,404.902,408.673,411.949,414.226,418.501,422.776,425.143,432.919,438.193,443.971,446.338,450.613,452.89,455.5,458.272,462.043,464.815,468.586,472.861,476.632,480.403,483.679,486.046,488.818,492.589,496.36,498.637,500.914,505.189,507.961,511.732,514.009,517.78,522.055,524.422,526.699,530.974,533.341,536.113,539.884,542.656" svgx:width="0.5,0.33,0.25,0.55,0.72,0.44,0.72,0.25,0.72,0.44,0.28,0.28,0.44,0.25,0.89,0.61,0.67,0.25,0.28,0.44,0.39,0.28,0.5,0.5,0.25,0.89,0.61,0.67,0.25,0.5,0.28,0.33,0.33,0.44,0.33,0.44,0.5,0.44,0.44,0.39,0.25,0.33,0.44,0.44,0.28,0.28,0.5,0.33,0.44,0.28,0.44,0.5,0.25,0.28,0.5,0.25,0.33,0.44,0.33,0.33" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">2) New Delta MTR lesion MTR differences (calibrated to ref-</text>
   <text y="451.059" x="342.01,345.781,348.553,352.324,356.599,360.37,364.141,366.517,369.793,373.564,377.335,381.61,384.382,386.758,389.53,392.302,396.577,403.354,405.73,410.005,413.776,416.548,420.823,423.595,427.366,429.742,432.019,435.79,439.066,441.343,445.618,449.893,452.269,456.04,460.315,464.59,468.361,472.132,474.904,478.675,482.95,486.721,490.492,492.868,495.145,499.42,501.796,505.072,507.349,511.12,515.395,517.672,521.443,523.819,526.591,530.362,534.133,538.408,542.683" svgx:width="0.44,0.33,0.44,0.5,0.44,0.44,0.25,0.39,0.44,0.44,0.5,0.33,0.25,0.33,0.33,0.5,0.78,0.25,0.5,0.44,0.33,0.5,0.33,0.44,0.25,0.28,0.44,0.39,0.28,0.5,0.5,0.25,0.44,0.5,0.5,0.44,0.44,0.33,0.44,0.5,0.44,0.44,0.25,0.28,0.5,0.25,0.39,0.28,0.44,0.5,0.28,0.44,0.25,0.33,0.44,0.44,0.5,0.5,0.33" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">erence scan) from before lesion appearance to stable recov-</text>
   <text y="462.057" x="342.01,345.781,348.553,352.828,354.178,356.95,361.666,365.941,367.291,374.068,378.343,382.618,384.895,389.17,392.446,393.796,398.071,402.346,405.622,407.899,409.249,411.526,415.297,418.573,420.85,425.125,429.4,430.75,434.521,438.796,443.071,446.842,450.613,453.385,457.156,461.431,465.202,468.973,471.745,473.77,475.12,479.899,483.67,487.441,491.716,495.991,500.266,504.037,506.809,511.084,512.434,516.205,520.48,524.755,529.03,533.305,535.582,539.857,542.134,545.635" svgx:width="0.44,0.33,0.5,0.25,0.33,0.55,0.5,0.25,0.78,0.5,0.5,0.28,0.5,0.39,0.25,0.5,0.5,0.39,0.28,0.25,0.28,0.44,0.39,0.28,0.5,0.5,0.25,0.44,0.5,0.5,0.44,0.44,0.33,0.44,0.5,0.44,0.44,0.33,0.25,0.25,0.56,0.44,0.44,0.5,0.5,0.5,0.44,0.33,0.5,0.25,0.44,0.5,0.5,0.5,0.5,0.28,0.5,0.28,0.39,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">ery (≥3 months post lesion appearance). Secondary endpoints </text>
   <text y="473.055" x="342.01,345.781,348.553,352.324,355.042,359.317,363.088,366.364,368.641,372.916,377.191,380.962,385.237,387.955,390.232,394.507,397.225,399.997,404.272,407.044,409.321,413.596,417.367,420.139,422.857,426.628,430.903,434.674,436.951,441.226,444.997,447.274,451.045,453.763,456.04,460.315,464.086,466.804,469.081,475.858,480.133,483.904,487.675,489.952,492.67,496.945,499.717,502.435,508.708,513.487,519.76,524.035,528.31,532.585,536.86,541.135,545.635" svgx:width="0.44,0.33,0.44,0.25,0.5,0.44,0.39,0.28,0.5,0.5,0.44,0.5,0.25,0.28,0.5,0.25,0.33,0.5,0.33,0.28,0.5,0.44,0.33,0.25,0.44,0.5,0.44,0.28,0.5,0.44,0.28,0.44,0.25,0.28,0.5,0.44,0.25,0.28,0.78,0.5,0.44,0.44,0.28,0.25,0.5,0.33,0.25,0.72,0.56,0.72,0.5,0.5,0.5,0.5,0.5,0.5,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">are designed to further evaluate the impact of GSK239512 </text>
   <text y="484.053" x="342.01,346.285,350.56,352.585,355.861,358.138,361.909,366.184,370.459,374.23,377.002,381.277,383.302,391.078,396.856,399.628,401.653,403.678,411.454,416.233,418.258,424.036,426.313,428.59,432.865,435.142,438.913,442.684,444.961,446.986,449.011,452.782,457.057,461.332,463.357,468.136,471.907,474.679,478.45,480.727,485.002,487.027,493.804,497.575,501.346,504.622,508.897,511.669,515.44,518.716" svgx:width="0.5,0.5,0.25,0.39,0.28,0.44,0.5,0.5,0.44,0.33,0.5,0.25,0.89,0.67,0.33,0.25,0.25,0.89,0.56,0.25,0.67,0.28,0.28,0.5,0.28,0.44,0.44,0.28,0.25,0.25,0.44,0.5,0.5,0.25,0.56,0.44,0.33,0.44,0.28,0.5,0.25,0.78,0.44,0.44,0.39,0.5,0.33,0.44,0.39,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">on standard MRI, MS Clinical, and Safety measures.</text>
   <text y="501.054" x="310.006,316.504,320.5,324.001,329.005,331.507,334.504,338.005,341.002" svgx:width="0.72,0.44,0.39,0.56,0.28,0.33,0.39,0.33,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPS-BoldMT;font-size:9.0px;stroke:none;">Results: </text>
   <text y="501.054" x="342.973,348.472,352.972,356.968,358.939,362.44,364.942,369.442,373.942,378.442,380.413,384.409,388.909,391.906,396.406,398.908,401.41,405.406,409.906,411.877,416.377,420.877,425.377,427.348,431.848,435.844,438.346,440.848,444.844,449.344,451.846,455.347,457.597,459.568,464.068,468.568,471.565,476.065,480.565,482.536,487.036,491.032,495.028,498.025,501.526,503.497,507.997,510.994,512.965,516.961,521.461,525.457,527.707,529.678,536.176,538.678,541.18,545.68" svgx:width="0.61,0.5,0.44,0.25,0.39,0.28,0.5,0.5,0.5,0.25,0.44,0.5,0.33,0.5,0.28,0.28,0.44,0.5,0.25,0.5,0.5,0.5,0.25,0.5,0.44,0.28,0.28,0.44,0.5,0.28,0.39,0.25,0.25,0.5,0.5,0.33,0.5,0.5,0.25,0.5,0.44,0.44,0.33,0.39,0.25,0.5,0.33,0.25,0.44,0.5,0.44,0.25,0.25,0.72,0.28,0.28,0.5,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">The study enrolled 131 patients, 18-50 years of age, with </text>
   <text y="512.052" x="310.006,316.009,322.012,330.013,335.017,337.078,340.075,344.575,349.075,353.575,358.075,360.136,363.133,367.129,371.629,374.131,377.632,381.628,386.128,388.189,396.19,400.186,406.684,411.184,415.684,419.68,422.182,426.682,428.743,432.739,435.736,438.238,440.74,444.736,447.733,450.235,454.231,457.228,459.478,461.539,465.535,470.035,472.096,477.595,482.095,486.595,490.591,495.091,499.591,503.587,508.087,510.148,516.646,519.148,522.649,526.645,531.145,533.647,536.149,538.651,541.153,545.653" svgx:width="0.67,0.67,0.89,0.56,0.25,0.33,0.5,0.5,0.5,0.5,0.25,0.33,0.44,0.5,0.28,0.39,0.44,0.5,0.25,0.89,0.44,0.72,0.5,0.5,0.44,0.28,0.5,0.25,0.44,0.33,0.28,0.28,0.44,0.33,0.28,0.44,0.33,0.25,0.25,0.44,0.5,0.25,0.61,0.5,0.5,0.44,0.5,0.5,0.44,0.5,0.25,0.72,0.28,0.39,0.44,0.5,0.28,0.28,0.28,0.28,0.5,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">RRMS (2010 revised McDonald criteria), an Expanded Disability </text>
   <text y="523.05" x="310.006,315.01,317.512,321.508,324.01,328.51,332.011,334.567,339.571,343.567,347.563,350.065,354.061,356.617,359.614,365.113,371.611,376.615,381.619,384.616,387.172,390.673,394.669,399.169,402.166,406.162,408.718,413.218,416.215,418.771,423.271,425.521,430.021,433.018,437.518,439.768,444.268,446.518,449.074,453.574,456.076,459.577,463.573,467.569,471.07,475.066,477.622,482.122,486.622,489.619,493.615,496.117,498.619,503.119,507.619" svgx:width="0.56,0.28,0.44,0.28,0.5,0.39,0.25,0.56,0.44,0.44,0.28,0.44,0.25,0.33,0.61,0.72,0.56,0.56,0.33,0.25,0.39,0.44,0.5,0.33,0.44,0.25,0.5,0.33,0.25,0.5,0.25,0.5,0.33,0.5,0.25,0.5,0.25,0.25,0.5,0.28,0.39,0.44,0.44,0.39,0.44,0.25,0.5,0.5,0.33,0.44,0.28,0.28,0.5,0.5,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">Status Scale (EDSS) score of 1.0-4.5, disease duration </text>
   <text y="523.05" x="510.175" svgx:width="0.55" style="fill:rgb(0,0,0);font-family:SymbolMT;font-size:9.0px;stroke:none;">≤</text>
   <text y="523.05" x="515.116,519.616,524.116,526.672,531.172,535.168,539.164,542.161,545.662" svgx:width="0.5,0.5,0.25,0.5,0.44,0.44,0.33,0.39,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">10 years </text>
   <text y="534.048" x="310.006,314.002,318.502,323.002,325.252,326.611,330.607,335.107,337.609,342.109,346.105,350.605,354.601,358.597,360.847,362.206,366.706,369.703,371.953,373.312,376.309,380.305,384.301,388.297,392.797,395.299,397.549,398.908,402.904,405.406,407.908,412.408,414.91,418.906,422.902,425.404,427.654,429.013,433.513,436.015,439.516,443.512,447.508,451.009,455.005,457.255,458.614,462.61,466.606,469.108,471.61,476.11,478.612,481.114,485.614,487.864,489.223,492.22,494.722,496.972,500.968,503.218,505.468,507.718,509.077,512.074,516.07,518.572,522.568,527.068,530.569,534.565,536.815,538.174,542.674,545.671" svgx:width="0.44,0.5,0.5,0.25,0.55,0.44,0.5,0.28,0.5,0.44,0.5,0.44,0.44,0.25,0.55,0.5,0.33,0.25,0.55,0.33,0.44,0.44,0.44,0.5,0.28,0.25,0.55,0.44,0.28,0.28,0.5,0.28,0.44,0.44,0.28,0.25,0.55,0.5,0.28,0.39,0.44,0.44,0.39,0.44,0.25,0.55,0.44,0.44,0.28,0.28,0.5,0.28,0.28,0.5,0.25,0.55,0.33,0.28,0.25,0.44,0.25,0.25,0.25,0.55,0.33,0.44,0.28,0.44,0.5,0.39,0.44,0.25,0.55,0.5,0.33,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">and evidence of recent clinical disease activity (i.e., relapse or </text>
   <text y="545.046" x="310.006,312.508,316.504,320.005,322.507,327.007,331.507,333.757,337.753,341.749,344.251,346.753,351.253,353.755,356.257,360.757,363.007,369.505,372.007,374.509,379.009,381.511,386.011,388.261,390.763,395.263,399.259,401.509,406.009,409.006,411.508,416.008,419.005,421.255,425.755,429.751,433.747,436.744,439.741" svgx:width="0.28,0.44,0.39,0.28,0.5,0.5,0.25,0.44,0.44,0.28,0.28,0.5,0.28,0.28,0.5,0.25,0.72,0.28,0.28,0.5,0.28,0.5,0.25,0.28,0.5,0.44,0.25,0.5,0.33,0.28,0.5,0.33,0.25,0.5,0.44,0.44,0.33,0.33,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">lesion activity within the prior year).</text>
   <text y="556.044" x="310.006,316.504,321.004,326.008,330.004,332.506,337.51,341.011,343.513,348.013,353.017,356.518,359.515" svgx:width="0.72,0.5,0.56,0.44,0.28,0.56,0.39,0.28,0.5,0.56,0.39,0.33,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPS-BoldMT;font-size:9.0px;stroke:none;">Conclusions: </text>
   <text y="556.044" x="362.782,369.28,372.781,375.283,379.783,384.283,386.533,387.55,391.546,396.046,400.042,404.542,409.042,413.038,416.539,418.789,419.806,422.308,426.808,429.058,430.075,438.076,443.575,449.578,451.828,454.078,455.095,457.597,462.097,464.599,468.1,470.35,471.367,474.868,477.37,481.87,486.37,490.87,493.12,494.137,496.639,500.14,502.39,503.407,507.907,511.903,515.404,517.906,522.406,526.906,530.902,535.402,537.652,538.669,541.171,545.671" svgx:width="0.72,0.39,0.28,0.5,0.5,0.25,0.55,0.44,0.5,0.44,0.5,0.5,0.44,0.39,0.25,0.55,0.28,0.5,0.25,0.55,0.89,0.61,0.67,0.25,0.25,0.55,0.28,0.5,0.28,0.39,0.25,0.55,0.39,0.28,0.5,0.5,0.5,0.25,0.55,0.28,0.39,0.25,0.55,0.5,0.44,0.39,0.28,0.5,0.5,0.44,0.5,0.25,0.55,0.28,0.5,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">Using changes in MTR, this study is designed to </text>
   <text y="567.042" x="310.006,314.002,317.503,320.005,324.001,328.501,331.003,333.505,337.006,341.506,344.026,346.528,351.028,355.024,357.544,361.54,366.04,368.542,371.044,373.546,376.048,380.548,383.068,387.568,390.565,393.085,399.583,404.587,411.085,415.585,420.085,424.585,429.085,433.585,438.085,440.605,443.107,447.607,450.127,454.627,457.624,462.124,469.126,473.626,476.128,480.124,482.644,485.146,489.142,492.643,495.145,499.645,504.145,506.665,509.662,513.658,520.66,525.16,529.156,531.658,534.16,538.66,542.656" svgx:width="0.44,0.39,0.28,0.44,0.5,0.28,0.28,0.39,0.5,0.25,0.28,0.5,0.44,0.25,0.44,0.5,0.28,0.28,0.28,0.28,0.5,0.25,0.5,0.33,0.25,0.72,0.56,0.72,0.5,0.5,0.5,0.5,0.5,0.5,0.25,0.28,0.5,0.25,0.5,0.33,0.5,0.78,0.5,0.28,0.44,0.25,0.28,0.44,0.39,0.28,0.5,0.5,0.25,0.33,0.44,0.78,0.5,0.44,0.28,0.28,0.5,0.44,0.33" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">establish the ability of GSK239512 to promote lesion remyelina-</text>
   <text y="578.04" x="310.006,312.508,315.01,319.51,324.01,326.26,328.51,330.085,335.089,339.085,343.081,347.581,352.081,356.581,360.577,363.574,368.074,370.324,371.899,379.9,385.903,388.9,391.15,392.725,396.721,401.221,405.721,407.971,409.546,413.542,416.044,418.546,423.046,425.548,429.544,433.54,436.042,438.292,439.867,443.863,448.363,452.863,457.363,461.863,464.365,468.865,471.367,474.868,477.118,478.693,485.191,487.693,490.195,492.697,494.947,496.522,500.518,504.019,507.52,510.022,513.523,516.025,518.275,519.85,522.352,526.852,529.102,530.677,535.177,539.173,541.675,545.671" svgx:width="0.28,0.28,0.5,0.5,0.25,0.25,0.55,0.56,0.44,0.44,0.5,0.5,0.5,0.44,0.33,0.5,0.25,0.55,0.89,0.67,0.33,0.25,0.55,0.44,0.5,0.5,0.25,0.55,0.44,0.28,0.28,0.5,0.28,0.44,0.44,0.28,0.25,0.55,0.44,0.5,0.5,0.5,0.5,0.28,0.5,0.28,0.39,0.25,0.55,0.72,0.28,0.28,0.28,0.25,0.55,0.44,0.39,0.39,0.28,0.39,0.28,0.25,0.55,0.28,0.5,0.25,0.55,0.5,0.44,0.28,0.44,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">tion. Secondary MRI and clinical endpoints will assist in data </text>
   <text y="589.038" x="310.006,312.508,317.008,319.51,323.506,326.503,331.003,334.0,337.996,340.498,344.494,346.996,349.498,353.998,358.498,360.667,364.663,369.163,373.663,375.832,378.334,382.834,385.003,387.505,392.005,396.001,398.17,402.67,406.666,410.167,412.669,417.169,421.669,423.838,428.338,431.335,433.504,436.501,441.001,443.503,448.003,451.0,454.996,457.165,460.666,463.168,467.668,472.168,474.67,478.666,482.167,484.336,486.838,491.338,493.507,496.009,500.509,503.011,507.007,510.004,513.001,517.501,522.001,525.997,528.499,532.495,534.664,537.166,541.666,545.662" svgx:width="0.28,0.5,0.28,0.44,0.33,0.5,0.33,0.44,0.28,0.44,0.28,0.28,0.5,0.5,0.25,0.44,0.5,0.5,0.25,0.28,0.5,0.25,0.28,0.5,0.44,0.25,0.5,0.44,0.39,0.28,0.5,0.5,0.25,0.5,0.33,0.25,0.33,0.5,0.28,0.5,0.33,0.44,0.25,0.39,0.28,0.5,0.5,0.28,0.44,0.39,0.25,0.28,0.5,0.25,0.28,0.5,0.28,0.44,0.33,0.33,0.5,0.5,0.44,0.28,0.44,0.25,0.28,0.5,0.44,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">interpretation and in the design of future studies to interrogate the </text>
   <text y="600.036" x="310.006,314.002,316.504,319.006,323.506,326.008,330.004,334.0,336.502,338.752,343.252,347.248,351.748,355.744,358.741,361.243,363.745,365.995,370.495,373.492,375.742,378.244,382.24,385.741,388.243,392.743,397.243,399.493,402.49,406.486,413.488,417.988,421.984,424.486,426.988,431.488,435.484,437.986,440.488,444.988,449.488,451.738,454.24,458.74,460.99,466.993,472.996,480.997,486.001,488.251,492.751,496.747,499.249,501.751,505.747,510.247,512.749,516.25" svgx:width="0.44,0.28,0.28,0.5,0.28,0.44,0.44,0.28,0.25,0.5,0.44,0.5,0.44,0.33,0.28,0.28,0.25,0.5,0.33,0.25,0.28,0.44,0.39,0.28,0.5,0.5,0.25,0.33,0.44,0.78,0.5,0.44,0.28,0.28,0.5,0.44,0.28,0.28,0.5,0.5,0.25,0.28,0.5,0.25,0.67,0.67,0.89,0.56,0.25,0.5,0.44,0.28,0.28,0.44,0.5,0.28,0.39,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">clinical benefit of lesion remyelination in RRMS patients.</text>
   <text y="627.036" x="310.006,315.505,320.005,324.505" svgx:width="0.61,0.5,0.5,0.5" style="fill:rgb(0,0,0);font-family:TimesNewRomanPS-BoldMT;font-size:9.0px;stroke:none;">P727</text>
   <text y="638.034" x="310.006,316.504,319.006,326.503,330.499,333.496,338.5,343.0,345.502,347.752,350.749,355.753,363.25,367.75,371.746,376.246,379.243,383.239,385.489,389.485,394.489,399.493,403.993,408.997,412.993,416.989,420.49,422.74,427.24,429.742,434.746,437.743,442.243,445.24,450.244,452.746,457.246,462.25,466.246,468.496,472.492,476.488,480.484,484.984,488.98,491.482,493.984,498.988,503.488" svgx:width="0.72,0.28,0.83,0.44,0.33,0.56,0.5,0.28,0.25,0.33,0.56,0.83,0.5,0.44,0.5,0.33,0.44,0.25,0.44,0.56,0.56,0.5,0.56,0.44,0.44,0.39,0.25,0.5,0.28,0.56,0.33,0.5,0.33,0.56,0.28,0.5,0.56,0.44,0.25,0.44,0.44,0.44,0.5,0.44,0.28,0.28,0.56,0.5,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPS-BoldMT;font-size:9.0px;stroke:none;">Dimethyl fumarate enhances glutathione recycling </text>
   <text y="649.032" x="310.006,315.01,319.51,321.76,324.262,329.266,333.262,337.258,341.254,345.754,349.255,351.757,356.761,361.261,363.511,367.507,372.007,377.011,381.007,385.003,388.504,392.005,394.507,399.007,404.011,406.261,410.761,415.765,420.769,423.019,426.016,431.02,436.024,440.02,443.017,445.519,450.019,455.023,457.273,461.773,464.77,467.02,471.52,474.022,479.026,482.023,486.523,489.52,494.524,497.026,501.526,506.53,510.526" svgx:width="0.56,0.5,0.25,0.28,0.56,0.44,0.44,0.44,0.5,0.39,0.28,0.56,0.5,0.25,0.44,0.5,0.56,0.44,0.44,0.39,0.39,0.28,0.5,0.56,0.25,0.5,0.56,0.56,0.25,0.33,0.56,0.56,0.44,0.33,0.28,0.5,0.56,0.25,0.5,0.33,0.25,0.5,0.28,0.56,0.33,0.5,0.33,0.56,0.28,0.5,0.56,0.44,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPS-BoldMT;font-size:9.0px;stroke:none;">by increasing expression and function of glutathione </text>
   <text y="660.03" x="310.006,314.002,317.998,323.002,328.006,332.002,334.999,339.499,343.0" svgx:width="0.44,0.44,0.56,0.56,0.44,0.33,0.5,0.39,0.44" style="fill:rgb(0,0,0);font-family:TimesNewRomanPS-BoldMT;font-size:9.0px;stroke:none;">reductase</text>
   <text y="671.028" x="310.006,316.504,318.754,324.253,326.755,330.256,334.252" svgx:width="0.72,0.25,0.61,0.28,0.39,0.44,0.5" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">D Lisak</text>
   <text y="668.592" x="338.761" svgx:width="0.5" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:5.85px;stroke:none;">1</text>
   <text y="671.112" x="341.686,343.936,346.186,352.189,354.439,360.937,365.437,368.434,371.431,378.433,382.429,386.929" svgx:width="0.25,0.25,0.67,0.25,0.72,0.5,0.33,0.33,0.78,0.44,0.5,0.5" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">, C Hoffmann</text>
   <text y="668.592" x="391.429" svgx:width="0.5" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:5.85px;stroke:none;">1</text>
   <text y="671.112" x="394.354,396.604,398.854,404.353,406.603,411.607,415.603,420.103,424.099,428.095,432.595" svgx:width="0.25,0.25,0.61,0.25,0.56,0.44,0.5,0.44,0.44,0.5,0.28" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">, T Schacht</text>
   <text y="668.592" x="435.096" svgx:width="0.5" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:5.85px;stroke:none;">1</text>
   <text y="671.112" x="438.021,440.271,442.521,449.019,451.269,459.27,463.266,465.768,470.268,474.768,478.764" svgx:width="0.25,0.25,0.72,0.25,0.89,0.44,0.28,0.5,0.5,0.44,0.33" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">, A Methner</text>
   <text y="668.592" x="481.761" svgx:width="0.5" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:5.85px;stroke:none;">1</text>
   <text y="679.59" x="310.017" svgx:width="0.5" style="fill:rgb(0,0,0);font-family:TimesNewRomanPS-ItalicMT;font-size:5.85px;stroke:none;">1</text>
   <text y="682.112" x="312.941,319.439,323.939,326.441,330.437,334.433,337.934,341.435,343.937,346.439,350.435,352.685,360.182,364.178,368.678,371.18,375.176,379.676,382.178,384.428,390.431,394.427,398.927,401.429,405.425,408.926,411.176,418.673,423.173,425.675,430.175,433.676,435.926,438.176,444.179,448.175,452.675,456.176,460.676,463.178,467.678,472.178,476.174,478.424,480.674,488.171,492.671,495.173,499.673,503.174,505.424,507.674,514.172,518.168,521.669,528.167,532.667,537.167" svgx:width="0.72,0.5,0.28,0.44,0.44,0.39,0.39,0.28,0.28,0.44,0.25,0.83,0.44,0.5,0.28,0.44,0.5,0.28,0.25,0.67,0.44,0.5,0.28,0.44,0.39,0.25,0.83,0.5,0.28,0.5,0.39,0.25,0.25,0.67,0.44,0.5,0.39,0.5,0.28,0.5,0.5,0.44,0.25,0.25,0.83,0.5,0.28,0.5,0.39,0.25,0.25,0.72,0.44,0.39,0.72,0.5,0.5,0.44" style="fill:rgb(0,0,0);font-family:TimesNewRomanPS-ItalicMT;font-size:9.0px;stroke:none;">University Medical Center Mainz, Neurology, Mainz, Germany</text>
   <text y="709.112" x="310.016,316.019,320.519,324.515,329.519,334.019,337.853,342.353,347.357,352.361,357.365,360.362" svgx:width="0.67,0.5,0.44,0.56,0.5,0.44,0.5,0.56,0.56,0.56,0.33,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPS-BoldMT;font-size:9.0px;stroke:none;">Background: </text>
   <text y="709.112" x="362.459,368.462,372.962,375.959,380.459,384.959,387.461,391.457,393.554,398.054,400.556,404.057,408.053,412.553,415.055,417.557,420.059,422.561,427.061,429.158,431.66,436.16,438.257,445.259,449.759,452.261,454.763,457.265,461.765,464.267,468.263,470.36,473.861,477.857,480.359,484.355,487.352,491.852,495.353,497.855,501.356,503.453,506.45,514.451,519.455,522.452,524.549,527.051,530.552,532.649,537.149,541.649,545.645" svgx:width="0.67,0.5,0.33,0.5,0.5,0.28,0.44,0.25,0.5,0.28,0.39,0.44,0.5,0.28,0.28,0.28,0.28,0.5,0.25,0.28,0.5,0.25,0.78,0.5,0.28,0.28,0.28,0.5,0.28,0.44,0.25,0.39,0.44,0.28,0.44,0.33,0.5,0.39,0.28,0.39,0.25,0.33,0.89,0.56,0.33,0.25,0.28,0.39,0.25,0.5,0.5,0.44,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">Chronic disability in multiple sclerosis (MS) is due </text>
   <text y="720.11" x="310.016,312.518,317.018,319.286,323.786,327.782,332.282,335.279,339.779,344.279,348.275,350.777,353.045,357.545,361.541,366.041,370.037,374.537,378.533,381.53,385.526,388.028,390.53,395.03,399.53,401.78,404.048,410.546,415.046,417.548,421.544,426.044,428.312,430.814,434.315,436.583,441.083,445.583,448.085,450.353,454.853,457.85,460.118,464.618,469.118,471.62,476.12,478.388,480.89,485.39,489.386,493.886,500.888,505.388,507.89,511.886,514.388,518.384,520.886,525.386,527.654,531.65,538.652,542.648" svgx:width="0.28,0.5,0.25,0.5,0.44,0.5,0.33,0.5,0.5,0.44,0.28,0.25,0.5,0.44,0.5,0.44,0.5,0.44,0.33,0.44,0.28,0.28,0.5,0.5,0.25,0.25,0.72,0.5,0.28,0.44,0.5,0.25,0.28,0.39,0.25,0.5,0.5,0.28,0.25,0.5,0.33,0.25,0.5,0.5,0.28,0.5,0.25,0.28,0.5,0.44,0.5,0.78,0.5,0.28,0.44,0.28,0.44,0.28,0.5,0.25,0.44,0.78,0.44,0.33" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">to neuronal degeneration, which is not or only incompletely ame-</text>
   <text y="731.108" x="310.016,314.516,318.512,323.012,325.514,329.51,331.454,333.956,338.456,340.4,342.902,349.904,356.906,361.406,365.906,370.406,377.408,381.908,386.408,390.908,393.41,397.406,399.908,404.408,407.405,411.905,413.849,416.351,420.851,424.847,427.844,431.84,436.34,440.255,442.505,444.287,449.786,454.286,458.282,460.226,464.726,469.226,473.726,477.722,480.719,483.221,487.721,490.223,494.723,499.223,501.167,508.169,512.165,516.161,520.661,524.657,529.157,531.659,535.16,542.162,545.663" svgx:width="0.5,0.44,0.5,0.28,0.44,0.25,0.28,0.5,0.25,0.28,0.78,0.78,0.5,0.5,0.5,0.78,0.5,0.5,0.5,0.28,0.44,0.28,0.5,0.33,0.5,0.25,0.28,0.5,0.44,0.33,0.44,0.5,0.5,0.25,0.25,0.61,0.5,0.44,0.25,0.5,0.5,0.5,0.44,0.33,0.28,0.5,0.28,0.5,0.5,0.25,0.78,0.44,0.44,0.5,0.44,0.5,0.28,0.39,0.78,0.39,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">nable to immunomodulatory therapy. The underlying mechanisms </text>
  </g>
 </g>
</svg>
